US5229272A
(en)
*
|
1989-04-25 |
1993-07-20 |
Igen, Inc. |
Catalytic antibody components
|
AU634186B2
(en)
*
|
1988-11-11 |
1993-02-18 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5196510A
(en)
*
|
1988-12-29 |
1993-03-23 |
Cytogen Corporation |
Molecular recognition units
|
EP0376851A3
(en)
*
|
1988-12-29 |
1991-06-26 |
Cytogen Corporation |
Molecular recognition units
|
US5116964A
(en)
*
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
*
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
DE3909799A1
(de)
|
1989-03-24 |
1990-09-27 |
Behringwerke Ag |
Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
|
US5236836A
(en)
*
|
1989-04-25 |
1993-08-17 |
Igen, Inc. |
Autoantibodies which enhance the rate of a chemical reaction
|
US5658753A
(en)
*
|
1989-04-25 |
1997-08-19 |
Paul; Sudhir |
Catalytic antibody components
|
US5602015A
(en)
*
|
1989-04-25 |
1997-02-11 |
Igen, Inc. |
Autoantibodies which enhance the rate of a chemical reaction
|
US5599538A
(en)
*
|
1989-04-25 |
1997-02-04 |
Igen, Inc. |
Autoantibodies which enhance the rate of a chemical reaction
|
US6048717A
(en)
*
|
1989-04-25 |
2000-04-11 |
Igen International, Inc. |
Inhibitors of catalytic antibodies
|
US5318897A
(en)
*
|
1989-04-25 |
1994-06-07 |
Igen, Inc. |
Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
|
US5194585A
(en)
*
|
1989-04-25 |
1993-03-16 |
Igen, Inc. |
Inhibitors of catalytic antibodies
|
US6291160B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6680192B1
(en)
|
1989-05-16 |
2004-01-20 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6969586B1
(en)
|
1989-05-16 |
2005-11-29 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291158B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291161B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
CA2016841C
(en)
*
|
1989-05-16 |
1999-09-21 |
William D. Huse |
A method for producing polymers having a preselected activity
|
US6291159B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US5231015A
(en)
*
|
1989-10-18 |
1993-07-27 |
Eastman Kodak Company |
Methods of extracting nucleic acids and pcr amplification without using a proteolytic enzyme
|
US6274324B1
(en)
|
1989-12-01 |
2001-08-14 |
Unilever Patent Holdings B.V. |
Specific binding reagent comprising a variable domain protein linked to a support or tracer
|
GB8928501D0
(en)
*
|
1989-12-18 |
1990-02-21 |
Unilever Plc |
Reagents
|
ES2225816T5
(es)
†
|
1990-02-01 |
2014-08-21 |
Siemens Healthcare Diagnostics Products Gmbh |
Producción y utilización de bancos de genes de anticuerpos humanos ("bibliotecas de anticuerpos humanos")
|
GB9021671D0
(en)
*
|
1990-10-05 |
1990-11-21 |
Unilever Plc |
Delivery of agents
|
US5427908A
(en)
*
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5723286A
(en)
*
|
1990-06-20 |
1998-03-03 |
Affymax Technologies N.V. |
Peptide library and screening systems
|
GB9206318D0
(en)
*
|
1992-03-24 |
1992-05-06 |
Cambridge Antibody Tech |
Binding substances
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
*
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9016299D0
(en)
*
|
1990-07-25 |
1990-09-12 |
Brien Caroline J O |
Binding substances
|
DE4033120A1
(de)
*
|
1990-10-18 |
1992-04-23 |
Boehringer Mannheim Gmbh |
Verfahren zur herstellung von chimaeren antikoerpern
|
US5571894A
(en)
*
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
AU1025692A
(en)
*
|
1991-02-06 |
1992-08-13 |
Ciba-Geigy Ag |
Novel chimeric antiidiotypic monoclonal antibodies
|
MX9203138A
(es)
*
|
1991-03-12 |
1992-09-01 |
Biogen Inc |
Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
|
CA2081028C
(en)
*
|
1991-03-12 |
1999-12-14 |
Barbara P. Wallner |
Cd2 binding domain of lymphocyte function associated antigen 3
|
EP0580737B1
(en)
*
|
1991-04-10 |
2004-06-16 |
The Scripps Research Institute |
Heterodimeric receptor libraries using phagemids
|
US5871907A
(en)
*
|
1991-05-15 |
1999-02-16 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US5858657A
(en)
*
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
US6492160B1
(en)
|
1991-05-15 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US5962255A
(en)
*
|
1992-03-24 |
1999-10-05 |
Cambridge Antibody Technology Limited |
Methods for producing recombinant vectors
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5939531A
(en)
*
|
1991-07-15 |
1999-08-17 |
Novartis Corp. |
Recombinant antibodies specific for a growth factor receptor
|
NL9101290A
(nl)
*
|
1991-07-23 |
1993-02-16 |
Stichting Rega V Z W |
Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
|
US6764681B2
(en)
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
US5270170A
(en)
*
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
US5733731A
(en)
*
|
1991-10-16 |
1998-03-31 |
Affymax Technologies N.V. |
Peptide library and screening method
|
ES2227512T3
(es)
*
|
1991-12-02 |
2005-04-01 |
Medical Research Council |
Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
|
AU665221B2
(en)
*
|
1991-12-02 |
1995-12-21 |
Cambridge Antibody Technology Limited |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
DE4142077A1
(de)
*
|
1991-12-19 |
1993-06-24 |
Boehringer Mannheim Gmbh |
Verfahren zur expression rekombinanter antikoerper
|
US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
US6399368B1
(en)
|
1992-01-17 |
2002-06-04 |
Board Of Regents, The University Of Texas System |
Secretion of T cell receptor fragments from recombinant Escherichia coli cells
|
CZ291039B6
(cs)
|
1992-02-06 |
2002-12-11 |
Schering Corporation |
Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek
|
US5733743A
(en)
*
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
WO1993022332A2
(en)
*
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
GB9216983D0
(en)
*
|
1992-08-11 |
1992-09-23 |
Unilever Plc |
Polypeptide production
|
US6765087B1
(en)
*
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
DE4233152A1
(de)
*
|
1992-10-02 |
1994-04-07 |
Behringwerke Ag |
Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
PT1231268E
(pt)
*
|
1994-01-31 |
2005-11-30 |
Univ Boston |
Bancos de anticorpos policlonais
|
US6010861A
(en)
*
|
1994-08-03 |
2000-01-04 |
Dgi Biotechnologies, Llc |
Target specific screens and their use for discovering small organic molecular pharmacophores
|
US6056957A
(en)
*
|
1994-08-04 |
2000-05-02 |
Schering Corporation |
Humanized monoclonal antibodies against human interleukin-5
|
WO1997008320A1
(en)
*
|
1995-08-18 |
1997-03-06 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Protein/(poly)peptide libraries
|
US6706484B1
(en)
|
1995-08-18 |
2004-03-16 |
Morphosys Ag |
Protein/(poly)peptide libraries
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
EP0898618B1
(en)
*
|
1996-05-10 |
2007-10-31 |
Novozymes A/S |
Method of providing novel dna sequences
|
ES2305012T3
(es)
|
1996-08-19 |
2008-11-01 |
Morphosys Ip Gmbh |
Secuencias de vectores/dna de bancos de anticuerpos combinatorios humanos.
|
GB9701425D0
(en)
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
CN1203178C
(zh)
|
1997-10-27 |
2005-05-25 |
尤尼利弗公司 |
多价抗原结合蛋白
|
JP2002502977A
(ja)
|
1998-02-04 |
2002-01-29 |
インビトロジェン コーポレイション |
マイクロアレイとその使用
|
EP1078051B1
(en)
|
1998-05-13 |
2007-12-12 |
Domantis Limited |
Phage-display system for the selection of correctly folded proteins
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
US7534605B2
(en)
|
1999-06-08 |
2009-05-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
|
US7297478B1
(en)
|
2000-09-22 |
2007-11-20 |
Large Scale Biology Corporation |
Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
|
US6656467B2
(en)
|
2000-01-27 |
2003-12-02 |
Medimmune, Inc. |
Ultra high affinity neutralizing antibodies
|
EP1264885A4
(en)
|
2000-02-22 |
2007-02-21 |
Med & Biological Lab Co Ltd |
ANTIBODY LIBRARY
|
DK1259547T3
(da)
|
2000-03-01 |
2012-10-15 |
Medimmune Inc |
Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
|
AU5358901A
(en)
*
|
2000-04-17 |
2001-10-30 |
Dyax Corp |
Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
EP1176200A3
(de)
|
2000-06-20 |
2005-01-12 |
Switch Biotech Aktiengesellschaft |
Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
|
KR20080074231A
(ko)
|
2000-06-29 |
2008-08-12 |
아보트 러보러터리즈 |
이중 특이성 항체 및 이의 제조 및 사용 방법
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
DE60126130T2
(de)
|
2000-11-17 |
2007-10-18 |
The University Of Rochester |
In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
EP1366191A2
(en)
|
2000-12-11 |
2003-12-03 |
Alexion Pharmaceuticals, Inc. |
Nested oligonucleotides containing hairpin for nucleic acid amplification
|
US6958213B2
(en)
|
2000-12-12 |
2005-10-25 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
ES2430857T3
(es)
|
2000-12-18 |
2013-11-22 |
Dyax Corp. |
Bibliotecas focalizadas de paquetes genéticos
|
US20020086292A1
(en)
|
2000-12-22 |
2002-07-04 |
Shigeaki Harayama |
Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
AU2002338446A1
(en)
*
|
2001-01-23 |
2002-11-05 |
University Of Rochester Medical Center |
Methods of producing or identifying intrabodies in eukaryotic cells
|
PL373835A1
(en)
|
2001-01-31 |
2005-09-19 |
Biogen Idec Inc. |
Use of cd23 antagonists for the treatment of neoplastic disorders
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
GB0115841D0
(en)
*
|
2001-06-28 |
2001-08-22 |
Medical Res Council |
Ligand
|
WO2004003019A2
(en)
|
2002-06-28 |
2004-01-08 |
Domantis Limited |
Immunoglobin single variant antigen-binding domains and dual-specific constructs
|
EP1399484B1
(en)
*
|
2001-06-28 |
2010-08-11 |
Domantis Limited |
Dual-specific ligand and its use
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
AU2002320352A1
(en)
|
2001-07-24 |
2003-02-17 |
Biogen Idec Ma Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
PT1419179E
(pt)
|
2001-08-10 |
2010-03-16 |
Univ Aberdeen |
Domínios de ligação de antigenes
|
WO2003018749A2
(en)
*
|
2001-08-22 |
2003-03-06 |
Shengfeng Li |
Compositions and methods for generating antigen-binding units
|
US20040005709A1
(en)
*
|
2001-10-24 |
2004-01-08 |
Hoogenboom Henricus Renerus Jacobus Mattheus |
Hybridization control of sequence variation
|
GB0126378D0
(en)
|
2001-11-02 |
2002-01-02 |
Oxford Biomedica Ltd |
Antigen
|
US7175983B2
(en)
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
CA2471116A1
(en)
*
|
2001-12-21 |
2003-07-03 |
Serge Muyldermans |
Method for cloning of variable domain sequences
|
EP2075256A2
(en)
|
2002-01-14 |
2009-07-01 |
William Herman |
Multispecific binding molecules
|
SI3031910T1
(en)
|
2002-02-21 |
2018-05-31 |
Institute Of Virology Slovak Academy Of Sciences |
MN / CA IX-SPECIFIC MONOCLONIC PROTECTOR GENERATED FROM MN / CA- DEFROSTABLE MICE AND METHOD OF APPLICATION
|
CA2481074A1
(en)
*
|
2002-04-05 |
2003-10-23 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
US7135310B2
(en)
|
2002-04-24 |
2006-11-14 |
The Regents Of The University Of California |
Method to amplify variable sequences without imposing primer sequences
|
HUE048922T2
(hu)
|
2002-05-22 |
2020-09-28 |
Novartis Ag |
Immunglobulin vázrégiók, amelyek intracelluláris környezetben fokozott stabilitást mutatnak, továbbá eljárások azonosításukra
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
JP4753578B2
(ja)
|
2002-06-03 |
2011-08-24 |
ジェネンテック, インコーポレイテッド |
合成抗体ファージライブラリー
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
GB0213745D0
(en)
|
2002-06-14 |
2002-07-24 |
Univ Edinburgh |
Enzyme
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
AU2003251238A1
(en)
|
2002-08-07 |
2004-02-25 |
Umc Utrecht Holding B.V. |
Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
DK2213685T3
(en)
|
2002-09-06 |
2014-03-03 |
Medarex Llc |
Therapeutic anti-IL-1R1 monoclonal antibody
|
AU2003299132A1
(en)
|
2002-10-07 |
2004-04-23 |
Genome Research Limited |
P53 binding polypeptide
|
WO2004034988A2
(en)
*
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
WO2004041865A2
(en)
*
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Stabilized single domain antibodies
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
JP2006523090A
(ja)
*
|
2002-12-27 |
2006-10-12 |
ドマンティス リミテッド |
リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
|
GB0230203D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
GB0230201D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Retargeting
|
CN101412759A
(zh)
|
2003-01-10 |
2009-04-22 |
埃博灵克斯股份有限公司 |
治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
|
ES2567198T3
(es)
*
|
2003-01-24 |
2016-04-20 |
Applied Molecular Evolution, Inc. |
Antagonistas de la IL-1 beta humana
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
RS54160B1
(sr)
|
2003-03-19 |
2015-12-31 |
Biogen Idec Ma Inc. |
Protein koji se vezuje za nogo receptor
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
EP1498133A1
(en)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma Deutschland GmbH |
Use of a pak inhibitor for the treatment of a joint disease
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
KR20060069825A
(ko)
*
|
2003-08-01 |
2006-06-22 |
제넨테크, 인크. |
제한된 다양성을 갖는 항체 cdr 폴리펩티드 서열
|
US20120202710A1
(en)
*
|
2003-09-09 |
2012-08-09 |
Integrigen, Inc. |
Methods and compositions for generation of germline human antibody genes
|
ES2339710T5
(es)
|
2003-09-23 |
2017-10-05 |
University Of North Carolina At Chapel Hill |
Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
|
EP1673450B1
(en)
|
2003-10-14 |
2010-04-28 |
Baxter International Inc. |
Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
|
EP1697415A1
(en)
|
2003-11-12 |
2006-09-06 |
Biogen Idec MA Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
JP4949038B2
(ja)
|
2003-12-01 |
2012-06-06 |
ダコ デンマーク アクティーゼルスカブ |
免疫組織化学的検出のための方法および組成物
|
GB0328690D0
(en)
|
2003-12-10 |
2004-01-14 |
Ludwig Inst Cancer Res |
Tumour suppressor protein
|
SG10201900535UA
(en)
|
2003-12-23 |
2019-02-27 |
Genentech Inc |
Novel anti-il 13 antibodies and uses thereof
|
CA2553692C
(en)
*
|
2004-01-20 |
2014-10-07 |
Kalobios, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
GB0406215D0
(en)
|
2004-03-19 |
2004-04-21 |
Procure Therapeutics Ltd |
Prostate stem cell
|
RU2429245C2
(ru)
|
2004-03-30 |
2011-09-20 |
Глаксо Груп Лимитед |
Иммуноглобулины
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
US8318905B2
(en)
|
2004-04-23 |
2012-11-27 |
Richard Kroczek |
Antibodies for depletion of ICOS-positive cells in vivo
|
EP1750747A1
(en)
|
2004-05-07 |
2007-02-14 |
Astellas US LLC |
Soluble lfa-3 polypeptide for treating viral disorders
|
KR20120133403A
(ko)
|
2004-06-01 |
2012-12-10 |
도만티스 리미티드 |
증강된 혈청 반감기를 가지는 이특이성 융합 항체
|
US7977071B2
(en)
|
2004-06-02 |
2011-07-12 |
Adalta Pty Ltd. |
Binding moieties based on shark ignar domains
|
CA2572193A1
(en)
|
2004-06-24 |
2006-01-05 |
Biogen Idec Ma Inc. |
Treatment of conditions involving oligodendrocytes with sp35 based agents
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
GB0414886D0
(en)
|
2004-07-02 |
2004-08-04 |
Neutec Pharma Plc |
Treatment of bacterial infections
|
KR101319848B1
(ko)
|
2004-07-20 |
2013-10-18 |
심포젠 에이/에스 |
재조합 폴리클로날 단백질 또는 폴리클로날 세포주의구조적 특성화 방법
|
AU2005263331B8
(en)
|
2004-07-20 |
2011-06-16 |
Symphogen A/S |
Anti-Rhesus D recombinant polyclonal antibody and methods of manufacture
|
SI2311874T1
(sl)
|
2004-07-22 |
2017-12-29 |
Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics |
Vezavne molekule
|
GB0416487D0
(en)
|
2004-07-23 |
2004-08-25 |
Isis Innovation |
Modified virus
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
WO2006055778A2
(en)
|
2004-11-16 |
2006-05-26 |
Kalobios, Inc. |
Immunoglobulin variable region cassette exchange
|
GB0425739D0
(en)
*
|
2004-11-23 |
2004-12-22 |
Procure Therapeutics Ltd |
Humanised baculovirus 2
|
GB0521621D0
(en)
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
FR2879605B1
(fr)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
EP1997890A1
(en)
|
2004-12-30 |
2008-12-03 |
Agency for Science, Technology and Research |
Chinese hamster apoptosis-related genes
|
ES2408704T3
(es)
|
2005-01-05 |
2013-06-21 |
Biogen Idec Ma Inc. |
Moléculas de unión a Cripto
|
CA2593328C
(en)
|
2005-01-14 |
2018-02-06 |
Ablynx N.V. |
Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets
|
CA2600209A1
(en)
|
2005-03-11 |
2006-09-14 |
Sanofi-Aventis |
Use of mgc4504
|
US20090325226A1
(en)
|
2005-03-15 |
2009-12-31 |
Stafford Darrel W |
Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
|
CA2601400A1
(en)
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
ES2432091T5
(es)
|
2005-03-25 |
2022-03-18 |
Gitr Inc |
Moléculas de unión GITR y usos de las mismas
|
EP1882044A1
(en)
|
2005-05-11 |
2008-01-30 |
sanofi-aventis |
Use of a gip promoter polymorphism
|
EP1888640B1
(en)
|
2005-05-18 |
2012-03-14 |
Ablynx N.V. |
Improved nanobodies against tumor necrosis factor-alpha
|
PA8675801A1
(es)
|
2005-05-19 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-mcp-1, composiciones, metodos y usos
|
PL3415535T3
(pl)
|
2005-05-20 |
2021-06-14 |
Ablynx N.V. |
Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
|
ES2547463T3
(es)
|
2005-06-17 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
Moléculas de unión a ILT3 y usos de las mismas
|
CN103172737A
(zh)
|
2005-06-30 |
2013-06-26 |
Abbvie公司 |
Il-12/p40结合蛋白
|
EP2238986A3
(en)
|
2005-07-08 |
2010-11-03 |
Biogen Idec MA Inc. |
Sp35 antibodies and uses thereof
|
AU2006283532B2
(en)
|
2005-08-19 |
2012-04-26 |
Abbvie Inc. |
Dual variable domain immunoglobin and uses thereof
|
EP2500353A3
(en)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US7807160B2
(en)
|
2005-08-31 |
2010-10-05 |
Schering Corporation |
Engineered anti-IL-23 antibodies
|
WO2007039256A2
(de)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
EP1937161B1
(en)
|
2005-10-03 |
2016-08-24 |
Smith and Nephew, Inc. |
Locking instrument assembly
|
DE102005048898A1
(de)
|
2005-10-12 |
2007-04-19 |
Sanofi-Aventis Deutschland Gmbh |
EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
|
GB0521139D0
(en)
|
2005-10-18 |
2005-11-23 |
Univ Sheffield |
Therapeutic agent
|
MX2008005405A
(es)
*
|
2005-10-28 |
2008-09-11 |
Florida Internat University Bo |
Anticuerpos quimericos equinos: humanos.
|
NZ568705A
(en)
|
2005-11-04 |
2012-07-27 |
Biogen Idec Inc |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
KR20180002911A
(ko)
|
2005-11-04 |
2018-01-08 |
제넨테크, 인크. |
안질환 치료를 위한 보체 경로 억제제의 용도
|
WO2007056441A2
(en)
|
2005-11-07 |
2007-05-18 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
JP2009516513A
(ja)
|
2005-11-21 |
2009-04-23 |
ラボラトワール セローノ ソシエテ アノニム |
ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用
|
CN101506236B
(zh)
|
2005-11-30 |
2012-12-12 |
雅培制药有限公司 |
抗淀粉样β蛋白的单克隆抗体及其用途
|
BRPI0619249A2
(pt)
|
2005-11-30 |
2011-09-20 |
Abbott Lab |
anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
|
EP1957536A2
(en)
*
|
2005-12-01 |
2008-08-20 |
Domantis Limited |
Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
|
WO2007064919A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
ES2388932T3
(es)
|
2005-12-02 |
2012-10-19 |
Genentech, Inc. |
Polipéptidos de unión y usos de los mismos
|
NZ598421A
(en)
|
2005-12-02 |
2013-11-29 |
Biogen Idec Inc |
Treatment of Conditions Involving Demyelination
|
JP2009518314A
(ja)
|
2005-12-02 |
2009-05-07 |
ジェネンテック・インコーポレーテッド |
Il−22に結合する抗体およびil−22rに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
|
US8669345B2
(en)
|
2006-01-27 |
2014-03-11 |
Biogen Idec Ma Inc. |
Nogo receptor antagonists
|
CN101400703B
(zh)
|
2006-02-01 |
2013-05-08 |
赛法隆澳大利亚控股有限公司 |
结构域抗体构建体
|
WO2007100711A2
(en)
|
2006-02-24 |
2007-09-07 |
Investigen, Inc. |
Methods and compositions for detecting polynucleotides
|
CA2646329C
(en)
|
2006-03-20 |
2018-07-03 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
EP1999147A1
(en)
*
|
2006-03-27 |
2008-12-10 |
Ablynx N.V. |
Medical delivery device for therapeutic proteins based on single domain antibodies
|
AU2007249408A1
(en)
*
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
WO2007140371A2
(en)
|
2006-05-30 |
2007-12-06 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
US7777008B2
(en)
|
2006-06-19 |
2010-08-17 |
Tolerx, Inc. |
ILT3 binding molecules and uses therefor
|
US8874380B2
(en)
|
2010-12-09 |
2014-10-28 |
Rutgers, The State University Of New Jersey |
Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
|
WO2008019061A2
(en)
*
|
2006-08-03 |
2008-02-14 |
Vaccinex, Inc. |
Anti-il-6 monoclonal antibodies and uses thereof
|
US10118970B2
(en)
|
2006-08-30 |
2018-11-06 |
Genentech, Inc. |
Multispecific antibodies
|
KR20090088852A
(ko)
|
2006-09-05 |
2009-08-20 |
메다렉스, 인코포레이티드 |
골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
|
UA115964C2
(uk)
|
2006-09-08 |
2018-01-25 |
Еббві Айрленд Анлімітед Компані |
Інтерлейкін-13-зв'язувальний білок
|
CA2662236A1
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
US8450464B2
(en)
|
2006-10-02 |
2013-05-28 |
Medarex, Inc. |
Human monoclonal antibodies that bind CXCR4
|
GB0620705D0
(en)
|
2006-10-18 |
2006-11-29 |
Opsona Therapeutics |
Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
|
EP2061814B1
(en)
|
2006-10-27 |
2012-06-06 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
DK2102239T3
(da)
|
2006-11-30 |
2012-05-29 |
Res Dev Foundation |
Forbedrede immunoglobulin-biblioteker
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
BRPI0717902A2
(pt)
|
2006-12-01 |
2013-10-29 |
Medarex Inc |
"anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
MX2009006277A
(es)
|
2006-12-14 |
2009-07-24 |
Medarex Inc |
Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
|
CA2671538A1
(en)
|
2006-12-14 |
2008-06-26 |
Leonard G. Presta |
Engineered anti-tslp antibody
|
CL2007003661A1
(es)
|
2006-12-18 |
2008-07-18 |
Genentech Inc |
Regiones de cadena pesada variable y liviana variable; acidos nucleicos que las codifican; metodo de produccion; anticuerpos anti-notch3 que las comprenden; y uso de los anticuerpos para tratar enfermedades relacionadas con el receptor notch3.
|
EP2557090A3
(en)
|
2006-12-19 |
2013-05-29 |
Ablynx N.V. |
Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
WO2008074840A2
(en)
|
2006-12-19 |
2008-06-26 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
|
US9512236B2
(en)
|
2006-12-19 |
2016-12-06 |
Ablynx N.V. |
Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
AU2008205244B2
(en)
|
2007-01-09 |
2013-02-07 |
Biogen Ma Inc. |
Sp35 antibodies and uses thereof
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
US7776331B1
(en)
|
2007-01-16 |
2010-08-17 |
Abbott Laboratories |
Methods of treating plaque psoriasis
|
WO2008092041A2
(en)
|
2007-01-24 |
2008-07-31 |
Carnegie Mellon University |
Optical biosensors
|
HUE042172T2
(hu)
|
2007-02-23 |
2019-06-28 |
Merck Sharp & Dohme |
Genetikailag elõállított anti-il-23P19 antitestek
|
WO2008103702A2
(en)
|
2007-02-23 |
2008-08-28 |
Investigen, Inc. |
Methods and compositions for rapid light-activated isolation and detection of analytes
|
EP2064242A1
(en)
|
2007-02-23 |
2009-06-03 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
DK2447719T3
(en)
|
2007-02-26 |
2016-10-10 |
Oxford Biotherapeutics Ltd |
proteins
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
AU2008219684B2
(en)
|
2007-02-28 |
2014-04-17 |
Merck Sharp & Dohme Corp. |
Engineered anti-IL-23R antibodies
|
WO2008121324A2
(en)
|
2007-03-30 |
2008-10-09 |
Abbott Laboratories |
Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
|
US9969797B2
(en)
*
|
2008-04-23 |
2018-05-15 |
Covalent Bioscience Incorporated |
Immunoglobulins directed to bacterial, viral and endogenous polypeptides
|
WO2008132516A1
(en)
|
2007-04-26 |
2008-11-06 |
Opsona Therapeutics Limited |
Toll-like receptor binding epitope and compositions for binding thereto
|
US20130195881A1
(en)
|
2007-04-27 |
2013-08-01 |
Sanjaya Singh |
Potent, stable and non-immunosuppressive anti-cd4 antibodies
|
DK2155789T3
(da)
*
|
2007-05-01 |
2013-10-21 |
Res Dev Foundation |
Immunoglobulin-Fc-biblioteker
|
MX2009012282A
(es)
|
2007-05-17 |
2009-11-25 |
Genentech Inc |
Estructuras cristalinas de fragmentos de neuropilina y complejos de neuropilina-anticuerpos.
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
MX2009012968A
(es)
*
|
2007-06-06 |
2010-04-01 |
Domantis Ltd |
Polipeptidos, dominios variables de anticuerpo y antagonistas.
|
MX2009013137A
(es)
|
2007-06-06 |
2010-04-30 |
Domantis Ltd |
Metodos para seleccionar polipeptidos resistentes a la proteasa.
|
GB0724331D0
(en)
|
2007-12-13 |
2008-01-23 |
Domantis Ltd |
Compositions for pulmonary delivery
|
CA2691075C
(en)
|
2007-06-15 |
2017-04-11 |
Daniela Gast |
Treatment of tumors using specific anti-l1 antibody
|
US8263072B2
(en)
|
2007-06-22 |
2012-09-11 |
Genera Istrazivanja, d.o.o. |
ADAMTS4 as a blood biomarker and therapeutic target for chronic renal failure
|
CA2691940C
(en)
|
2007-07-03 |
2018-03-06 |
Joost Alexander Kolkman |
Methods for providing improved immunoglobulin sequences
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
EP2023144A1
(en)
|
2007-08-01 |
2009-02-11 |
Sanofi-Aventis |
Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
|
EP2170366B1
(en)
|
2007-08-03 |
2013-11-06 |
Opsona Therapeutics Limited |
Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage
|
SI2195023T1
(en)
|
2007-08-29 |
2018-07-31 |
Sanofi |
Humanized anti-CXCR5 antibodies, their derivatives and their uses
|
EP2197491A4
(en)
|
2007-09-04 |
2011-01-12 |
Univ California |
HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER
|
BRPI0816785A2
(pt)
|
2007-09-14 |
2017-05-02 |
Adimab Inc |
bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
CN101836117B
(zh)
|
2007-09-18 |
2014-07-23 |
丹麦达科有限公司 |
用于检测生物靶点的快速和灵敏的方法
|
SG10201605394SA
(en)
|
2007-09-26 |
2016-08-30 |
Chugai Pharmaceutical Co Ltd |
Modified Antibody Constant Region
|
EP2535349A1
(en)
|
2007-09-26 |
2012-12-19 |
UCB Pharma S.A. |
Dual specificity antibody fusions
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
US20090202475A1
(en)
|
2007-11-07 |
2009-08-13 |
Genentech, Inc. |
Compositions and methods for treatment of microbial disorders
|
US7892760B2
(en)
|
2007-11-19 |
2011-02-22 |
Celera Corporation |
Lung cancer markers, and uses thereof
|
JP5745272B2
(ja)
|
2007-11-19 |
2015-07-08 |
ジェネンテック, インコーポレイテッド |
腫瘍進行を阻害するための組成物及び方法
|
WO2009068630A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Immunoglobulin constructs
|
JP5781764B2
(ja)
|
2007-11-27 |
2015-09-24 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
14−3−3η抗体、並びに関節炎の診断及び治療のためのその使用
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
WO2009079212A2
(en)
|
2007-12-03 |
2009-06-25 |
Carnegie Mellon University |
Linked peptide fluorogenic biosensors
|
PT2594590E
(pt)
|
2007-12-14 |
2015-01-14 |
Bristol Myers Squibb Co |
Moléculas de ligação ao recetor humano ox40
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
SG10201605629VA
(en)
|
2008-01-03 |
2016-08-30 |
Scripps Research Inst |
Antibody targeting through a modular recognition domain
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2098536A1
(en)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation and identification of antigen- or ligand-specific binding proteins
|
US20110091462A1
(en)
|
2008-03-05 |
2011-04-21 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making and uses thereof
|
US9873957B2
(en)
*
|
2008-03-13 |
2018-01-23 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
RU2497545C2
(ru)
|
2008-03-18 |
2013-11-10 |
Эбботт Лэборетриз |
Способ лечения псориаза (варианты)
|
EP2105742A1
(en)
|
2008-03-26 |
2009-09-30 |
Sanofi-Aventis |
Use of cathepsin C
|
AU2009228158B2
(en)
|
2008-03-27 |
2014-02-27 |
Zymogenetics, Inc. |
Compositions and methods for inhibiting PDGFRbeta and VEGF-A
|
AU2009231733B2
(en)
*
|
2008-03-31 |
2015-12-24 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing asthma
|
WO2009124931A2
(en)
|
2008-04-07 |
2009-10-15 |
Ablynx Nv |
Amino acid sequences directed against the notch pathways and uses thereof
|
AU2008201871A1
(en)
*
|
2008-04-16 |
2009-11-26 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Inhibition of angiogenesis and tumor metastasis
|
WO2009132287A2
(en)
|
2008-04-24 |
2009-10-29 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
|
CA2722466A1
(en)
|
2008-04-29 |
2009-11-05 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
EP2116618A1
(en)
|
2008-05-09 |
2009-11-11 |
Agency for Science, Technology And Research |
Diagnosis and treatment of Kawasaki disease
|
KR101649189B1
(ko)
|
2008-05-09 |
2016-08-18 |
애브비 인코포레이티드 |
최종 당화 산물의 수용체(rage)에 대한 항체 및 이의 용도
|
US9212226B2
(en)
|
2008-05-16 |
2015-12-15 |
Ablynx N.V. |
Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
|
AU2009256250B2
(en)
|
2008-06-03 |
2013-05-30 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
CA2725666A1
(en)
|
2008-06-03 |
2009-12-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
DK2285408T3
(en)
|
2008-06-05 |
2019-02-04 |
Ablynx Nv |
AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
|
WO2009155484A2
(en)
|
2008-06-20 |
2009-12-23 |
Wyeth |
Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
|
NZ590074A
(en)
|
2008-07-08 |
2012-12-21 |
Abbott Lab |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
RU2559525C2
(ru)
|
2008-07-08 |
2015-08-10 |
Эббви Инк |
Белки, связывающие простагландин е2, и их применение
|
AU2009269099B2
(en)
|
2008-07-09 |
2016-03-10 |
Biogen Ma Inc. |
Compositions comprising antibodies to LINGO or fragments thereof
|
JP5924937B2
(ja)
|
2008-07-25 |
2016-05-25 |
エックス−ボディ インコーポレイテッド |
タンパク質スクリーニング法
|
EP2331107A4
(en)
|
2008-08-08 |
2011-08-24 |
Agency Science Tech & Res |
VHZ FOR DIAGNOSIS AND TREATMENT OF CANCERS
|
US8795981B2
(en)
|
2008-08-08 |
2014-08-05 |
Molecular Devices, Llc |
Cell detection
|
NZ590816A
(en)
|
2008-08-14 |
2013-02-22 |
Cephalon Australia Pty Ltd |
Anti-il-12/il-23 antibodies
|
JP5796831B2
(ja)
|
2008-09-03 |
2015-10-21 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体
|
MX2011002478A
(es)
|
2008-09-07 |
2011-04-05 |
Glyconex Inc |
Anticuerpo anti-glucoesfingolipido tipo i extendido, derivados del mismo y su uso.
|
US9075065B2
(en)
|
2008-09-12 |
2015-07-07 |
Dako Denmark A/S |
Prostate cancer biomarker
|
US8417011B2
(en)
|
2008-09-18 |
2013-04-09 |
Molecular Devices (New Milton) Ltd. |
Colony detection
|
CA2744523A1
(en)
*
|
2008-09-22 |
2010-03-25 |
Calmune Corporation |
Methods and vectors for display of molecules and displayed molecules and collections
|
US20100081575A1
(en)
*
|
2008-09-22 |
2010-04-01 |
Robert Anthony Williamson |
Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
|
CA2738605A1
(en)
|
2008-09-24 |
2010-04-01 |
Luke Anthony O'neill |
Composition and method for treatment of preterm labor
|
DK2334705T3
(en)
|
2008-09-26 |
2017-03-27 |
Ucb Biopharma Sprl |
BIOLOGICAL PRODUCTS
|
EP2352764B1
(en)
|
2008-10-14 |
2018-03-28 |
Ablynx N.V. |
AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
|
WO2010056550A1
(en)
|
2008-10-29 |
2010-05-20 |
Wyeth Llc |
Methods for purification of single domain antigen binding molecules
|
CN102271707B
(zh)
|
2008-10-29 |
2015-04-08 |
阿布林克斯公司 |
单域抗原结合性分子的制剂
|
JP2012508017A
(ja)
|
2008-11-07 |
2012-04-05 |
ファブラス エルエルシー |
抗dll4抗体及びその使用
|
JP5823871B2
(ja)
|
2008-12-10 |
2015-11-25 |
アブリンクス エン.ヴェー. |
血管新生に関連した疾患及び障害の治療のための、アンジオポイエチン/Tieシステムに指向性を有するアミノ酸配列及びこれを含むポリペプチド
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
US9260508B2
(en)
|
2008-12-19 |
2016-02-16 |
Ablynx N.V. |
Method for generation of immunoglobulin sequences
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
CN102341411A
(zh)
|
2008-12-31 |
2012-02-01 |
比奥根艾迪克Ma公司 |
抗-淋巴细胞毒素抗体
|
US20120058131A1
(en)
|
2009-01-21 |
2012-03-08 |
Oxford Biotherapeutics Ltd |
Pta089 protein
|
US20100260752A1
(en)
|
2009-01-23 |
2010-10-14 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
|
TW201031421A
(en)
|
2009-01-29 |
2010-09-01 |
Abbott Lab |
IL-1 binding proteins
|
EP2219029A1
(en)
|
2009-01-30 |
2010-08-18 |
Sanofi-Aventis |
Test systems, methods and uses involving AS160 protein
|
EP2398504B1
(en)
|
2009-02-17 |
2018-11-28 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
US8435735B2
(en)
|
2009-02-19 |
2013-05-07 |
Dako Denmark A/S |
Methods and compounds for detection of molecular targets
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
NZ594514A
(en)
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
WO2010100437A2
(en)
|
2009-03-05 |
2010-09-10 |
University Of Sheffield |
Production of protein
|
PL2403878T3
(pl)
|
2009-03-05 |
2017-12-29 |
E. R. Squibb & Sons, L.L.C. |
W pełni ludzkie przeciwciała specyficzne dla CADM1
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
KR101456326B1
(ko)
|
2009-04-07 |
2014-11-12 |
로슈 글리카트 아게 |
3가, 이중특이적 항체
|
US8748581B2
(en)
|
2009-04-10 |
2014-06-10 |
Ablynx N.V. |
Anti-IL-6R polypeptides and pharmaceutical compositions thereof
|
EP2421898B1
(en)
|
2009-04-20 |
2016-03-16 |
Oxford BioTherapeutics Ltd |
Antibodies specific to cadherin-17
|
CN102459340A
(zh)
*
|
2009-04-23 |
2012-05-16 |
特罗科隆科学有限公司 |
粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
|
PT2424889E
(pt)
|
2009-04-30 |
2015-11-12 |
Ablynx Nv |
Método de produção de anticorpos de domínio
|
WO2010135558A1
(en)
*
|
2009-05-20 |
2010-11-25 |
Novimmune S.A. |
Systhetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
|
CN102449149B
(zh)
|
2009-05-29 |
2014-04-23 |
莫佛塞斯公司 |
集合及其使用方法
|
SG176095A1
(en)
|
2009-06-05 |
2011-12-29 |
Ablynx Nv |
Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
EP2448972A4
(en)
*
|
2009-06-30 |
2012-11-28 |
Res Dev Foundation |
IMMUNOGLOBULIN FC POLYPEPTIDES
|
JP2012531212A
(ja)
|
2009-07-03 |
2012-12-10 |
アビペップ ピーティーワイ リミテッド |
イムノコンジュゲート及びその作製方法
|
IE20090514A1
(en)
|
2009-07-06 |
2011-02-16 |
Opsona Therapeutics Ltd |
Humanised antibodies and uses therof
|
WO2011003622A1
(en)
|
2009-07-10 |
2011-01-13 |
Ablynx N.V. |
Method for the production of variable domains
|
AR077595A1
(es)
|
2009-07-27 |
2011-09-07 |
Genentech Inc |
Tratamientos de combinacion
|
TWI465250B
(zh)
|
2009-08-29 |
2014-12-21 |
Abbvie Inc |
治療用之dll4結合蛋白質
|
JP5715137B2
(ja)
|
2009-08-31 |
2015-05-07 |
アボット・ラボラトリーズAbbott Laboratories |
主要有害心イベントの予測のためのバイオマーカーおよびその使用
|
EP2293072A1
(en)
|
2009-08-31 |
2011-03-09 |
Sanofi-Aventis |
Use of cathepsin H
|
IN2012DN02737A
(ja)
|
2009-09-01 |
2015-09-11 |
Abbott Lab |
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US8709424B2
(en)
|
2009-09-03 |
2014-04-29 |
Merck Sharp & Dohme Corp. |
Anti-GITR antibodies
|
EP2473527B1
(en)
|
2009-09-03 |
2016-11-30 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
AU2010291902A1
(en)
*
|
2009-09-14 |
2012-04-05 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
SG179135A1
(en)
|
2009-09-14 |
2012-05-30 |
Abbott Lab |
Methods for treating psoriasis
|
CN104945509A
(zh)
|
2009-09-16 |
2015-09-30 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
WO2011047083A1
(en)
|
2009-10-13 |
2011-04-21 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
KR20140015139A
(ko)
|
2009-10-15 |
2014-02-06 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
EP2488186B1
(en)
|
2009-10-16 |
2017-05-24 |
National University of Singapore |
Anti-neoplastic uses of artemin antagonists
|
WO2011047680A1
(en)
|
2009-10-20 |
2011-04-28 |
Dako Denmark A/S |
Immunochemical detection of single target entities
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
JO3437B1
(ar)
|
2009-10-30 |
2019-10-20 |
Esai R & D Man Co Ltd |
أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
EP2496605A1
(en)
|
2009-11-02 |
2012-09-12 |
Oxford Biotherapeutics Ltd. |
Ror1 as therapeutic and diagnostic target
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
EP2496600A1
(en)
|
2009-11-04 |
2012-09-12 |
Fabrus LLC |
Methods for affinity maturation-based antibody optimization
|
MY162511A
(en)
|
2009-11-04 |
2017-06-15 |
Merck Sharp & Dohme |
Engineered anti-tslp antibody
|
WO2011054893A2
(en)
|
2009-11-05 |
2011-05-12 |
Novartis Ag |
Biomarkers predictive of progression of fibrosis
|
WO2011058087A1
(en)
|
2009-11-11 |
2011-05-19 |
Gentian As |
Immunoassay for assessing related analytes of different origin
|
EP2507262A1
(en)
|
2009-11-30 |
2012-10-10 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
EP3511023A1
(en)
|
2009-12-02 |
2019-07-17 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
CN102656190A
(zh)
|
2009-12-08 |
2012-09-05 |
雅培股份有限两合公司 |
用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
|
ES2565208T3
(es)
|
2009-12-11 |
2016-04-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-VEGF-C y métodos de uso de los mismos
|
EP2513145B1
(en)
|
2009-12-14 |
2018-01-24 |
Ablynx N.V. |
Single variable domain antibodies against ox40l, constructs and therapeutic use
|
CN107095846A
(zh)
|
2009-12-21 |
2017-08-29 |
霍夫曼-拉罗奇有限公司 |
抗体配制剂
|
MX2012007379A
(es)
|
2009-12-23 |
2012-08-31 |
Genentech Inc |
Anticuerpos anti-bv8 y usos de los mismos.
|
SG181814A1
(en)
|
2009-12-23 |
2012-07-30 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them 2
|
WO2011083140A1
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4
|
AR079944A1
(es)
|
2010-01-20 |
2012-02-29 |
Boehringer Ingelheim Int |
Anticuerpo neutralizante de la actividad de un anticoagulante
|
KR20130028055A
(ko)
|
2010-01-28 |
2013-03-18 |
글락소 그룹 리미티드 |
Cd 127 결합 단백질
|
EP2354159A1
(en)
|
2010-02-05 |
2011-08-10 |
RWTH Aachen |
CCL17 inhibitors for use in T helper cell-driven diseases
|
KR20120125357A
(ko)
|
2010-02-10 |
2012-11-14 |
노파르티스 아게 |
근육 성장을 위한 방법 및 화합물
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
CN105380904A
(zh)
|
2010-02-11 |
2016-03-09 |
埃博灵克斯股份有限公司 |
用于制备气雾剂的方法和组合物
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
EP2542582A4
(en)
|
2010-03-02 |
2013-12-04 |
Abbvie Inc |
THERAPEUTIC PROTEINS LINKING TO DLL4
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
AU2011227335B2
(en)
|
2010-03-17 |
2014-11-06 |
Abbott Research B.V. |
Anti-nerve growth factor (NGF) antibody compositions
|
BR112012022044A2
(pt)
|
2010-03-24 |
2020-08-25 |
Genentech Inc |
''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
|
US8937164B2
(en)
|
2010-03-26 |
2015-01-20 |
Ablynx N.V. |
Biological materials related to CXCR7
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
MX360403B
(es)
|
2010-04-15 |
2018-10-31 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
EP4234698A3
(en)
|
2010-05-06 |
2023-11-08 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
BR112012028326A2
(pt)
|
2010-05-06 |
2017-03-21 |
Novartis Ag |
anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
|
EP2571532B1
(en)
|
2010-05-14 |
2017-05-03 |
Abbvie Inc. |
Il-1 binding proteins
|
EP3546483A1
(en)
|
2010-05-20 |
2019-10-02 |
Ablynx N.V. |
Biological materials related to her3
|
EP2577309B1
(en)
|
2010-05-25 |
2016-11-23 |
Carnegie Mellon University |
Targeted probes of cellular physiology
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
KR20130098165A
(ko)
|
2010-06-03 |
2013-09-04 |
제넨테크, 인크. |
항체 및 면역접합체의 이뮤노-pet 영상화 및 그의 용도
|
WO2011161545A2
(en)
|
2010-06-04 |
2011-12-29 |
The Netherlands Cancer Institute |
Non-hydrolyzable protein conjugates, methods and compositions related thereto
|
WO2011158019A1
(en)
|
2010-06-16 |
2011-12-22 |
Adjuvantix Limited |
Polypeptide vaccine
|
MX336001B
(es)
|
2010-06-18 |
2016-01-07 |
Genentech Inc |
Anticuerpos anti-axl y metodos de uso.
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
SG186983A1
(en)
|
2010-07-09 |
2013-02-28 |
Genentech Inc |
Anti-neuropilin antibodies and methods of use
|
EP2591006B1
(en)
|
2010-07-09 |
2019-04-24 |
Bioverativ Therapeutics Inc. |
Processable single chain molecules and polypeptides made using same
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
MX360336B
(es)
|
2010-07-16 |
2018-10-30 |
Adimab Llc Star |
Colecciones de anticuerpos.
|
MX341309B
(es)
|
2010-07-20 |
2016-08-12 |
Cephalon Australia Pty Ltd |
Anticuerpos especificos del heterodimero de anti-il-23.
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
CA2806855A1
(en)
|
2010-08-03 |
2012-02-09 |
F. Hoffmann - La Roche Ag |
Chronic lymphocytic leukemia (cll) biomarkers
|
CA2807014A1
(en)
|
2010-08-03 |
2012-02-09 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
JP2013541937A
(ja)
|
2010-08-05 |
2013-11-21 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗mhc抗体−抗ウイルス性サイトカイン融合タンパク質
|
HUE036077T2
(hu)
|
2010-08-13 |
2018-06-28 |
Roche Glycart Ag |
Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
|
WO2012020096A1
(en)
|
2010-08-13 |
2012-02-16 |
Medimmune Limited |
Monomeric polypeptides comprising variant fc regions and methods of use
|
BR112013002444A2
(pt)
|
2010-08-13 |
2016-05-24 |
Roche Glycart Ag |
anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
|
JP6147665B2
(ja)
|
2010-08-14 |
2017-06-14 |
アッヴィ・インコーポレイテッド |
アミロイドベータ結合タンパク質
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
RS63063B1
(sr)
|
2010-08-19 |
2022-04-29 |
Zoetis Belgium S A |
Anti-ngf antitela i njihova upotreba
|
EA036314B1
(ru)
|
2010-08-20 |
2020-10-26 |
Новартис Аг |
Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
TW201215405A
(en)
|
2010-08-25 |
2012-04-16 |
Hoffmann La Roche |
Antibodies against IL-18R1 and uses thereof
|
TW201211252A
(en)
|
2010-08-26 |
2012-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
EP3556396B1
(en)
|
2010-08-31 |
2022-04-20 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
US20120089541A1
(en)
|
2010-08-31 |
2012-04-12 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
JP6121904B2
(ja)
|
2010-09-08 |
2017-04-26 |
ハロザイム インコーポレイテッド |
条件的活性治療用タンパク質を評価および同定する、または発展させる方法
|
SG10201506906VA
(en)
|
2010-09-09 |
2015-10-29 |
Pfizer |
4-1bb binding molecules
|
WO2012038744A2
(en)
|
2010-09-22 |
2012-03-29 |
Genome Research Limited |
Detecting mutations
|
US8497138B2
(en)
|
2010-09-30 |
2013-07-30 |
Genetix Limited |
Method for cell selection
|
GB201016494D0
(en)
|
2010-09-30 |
2010-11-17 |
Queen Mary Innovation Ltd |
Polypeptide
|
EP2625197B1
(en)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
NO2632946T3
(ja)
|
2010-10-29 |
2018-05-05 |
|
|
JP6167040B2
(ja)
|
2010-11-05 |
2017-07-19 |
ザイムワークス,インコーポレイテッド |
Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
|
EP2638068B1
(en)
|
2010-11-08 |
2018-12-26 |
Novartis AG |
Cxcr2 binding polypeptides
|
US10180426B2
(en)
|
2010-11-08 |
2019-01-15 |
Dako Denmark A/S |
Quantification of single target molecules in histological samples
|
AR083819A1
(es)
|
2010-11-10 |
2013-03-27 |
Genentech Inc |
UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
|
JP6253986B2
(ja)
|
2010-11-19 |
2017-12-27 |
モルフォシス・アーゲー |
コレクション及びその使用方法
|
WO2012076010A1
(en)
|
2010-12-06 |
2012-06-14 |
Dako Denmark A/S |
Combined histological stain
|
BR112013013460A8
(pt)
|
2010-12-16 |
2019-02-12 |
Genentech Inc |
métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total
|
TW201238974A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201238973A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201239097A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201241179A
(en)
|
2010-12-17 |
2012-10-16 |
Sanofi Sa |
MiRNAs in joint disease
|
CN107098972A
(zh)
|
2010-12-20 |
2017-08-29 |
霍夫曼-拉罗奇有限公司 |
抗间皮素抗体和免疫偶联物
|
US9631002B2
(en)
|
2010-12-21 |
2017-04-25 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin K-dependent proteins
|
RU2627171C2
(ru)
|
2010-12-21 |
2017-08-03 |
Эббви Инк. |
Il-1 альфа и бета биспецифические иммуноглобулины с двойными вариабельными доменами и их применение
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
EA201390929A1
(ru)
|
2010-12-22 |
2013-12-30 |
Дженентек, Инк. |
Антитела к pcsk9 и способы их применения
|
WO2012085069A2
(en)
|
2010-12-23 |
2012-06-28 |
Roche Diagnostics Gmbh |
Detection of a polypeptide dimer by a bivalent binding agent
|
CN103384825B
(zh)
|
2010-12-23 |
2017-05-24 |
霍夫曼-拉罗奇有限公司 |
通过二价结合剂检测经翻译后修饰的多肽
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
CN103384681B
(zh)
|
2010-12-23 |
2018-05-18 |
霍夫曼-拉罗奇有限公司 |
结合剂
|
EP2471554A1
(en)
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
JP2014504503A
(ja)
|
2010-12-28 |
2014-02-24 |
ゾーマ テクノロジー リミテッド |
Pdzドメインを用いた細胞表面提示
|
AU2012214643B2
(en)
|
2011-02-07 |
2016-12-15 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides
|
CN103476433A
(zh)
|
2011-02-10 |
2013-12-25 |
罗切格利卡特公司 |
改良的免疫疗法
|
CA2827170A1
(en)
|
2011-02-11 |
2012-08-16 |
David M. Hilbert |
Monovalent and multivalent multispecific complexes and uses thereof
|
EP2681239B8
(en)
|
2011-02-28 |
2015-09-09 |
F. Hoffmann-La Roche AG |
Antigen binding proteins
|
EP2681240B1
(en)
|
2011-02-28 |
2017-08-16 |
F. Hoffmann-La Roche AG |
Monovalent antigen binding proteins
|
EP2686016B1
(en)
|
2011-03-14 |
2019-05-01 |
Cellmid Limited |
Antibody recognizing n-domain of midkine
|
PL3235508T3
(pl)
|
2011-03-16 |
2021-07-12 |
Sanofi |
Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
|
PT2691415T
(pt)
|
2011-03-28 |
2018-10-19 |
Ablynx Nv |
Método para produção de formulações sólidas compreendendo domínios variáveis únicos de imunoglobulina
|
EP2691418A1
(en)
|
2011-03-28 |
2014-02-05 |
Ablynx N.V. |
Bispecific anti-cxcr7 immunoglobulin single variable domains
|
EP3590965A1
(en)
|
2011-03-29 |
2020-01-08 |
Roche Glycart AG |
Antibody fc variants
|
AP2013007046A0
(en)
|
2011-03-30 |
2013-08-31 |
Boehringer Ingelheim Int |
Anticoagulant antidotes
|
MX342240B
(es)
|
2011-04-07 |
2016-09-21 |
Genentech Inc |
Anticuerpos anti-fgfr4 y metodos de uso.
|
EP2511293A1
(en)
|
2011-04-13 |
2012-10-17 |
LEK Pharmaceuticals d.d. |
A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
|
EP2699691B1
(en)
|
2011-04-19 |
2017-10-18 |
Dako Denmark A/S |
New method for enzyme-mediated signal amplification
|
CA2828662A1
(en)
|
2011-04-20 |
2012-10-26 |
Roche Glycart Ag |
Method and constructs for the ph dependent passage of the blood-brain-barrier
|
JP6038121B2
(ja)
|
2011-04-21 |
2016-12-07 |
ガーバン インスティテュート オブ メディカル リサーチ |
修飾された可変ドメイン分子及びその製造及び使用の方法b
|
EP2518157A1
(en)
|
2011-04-26 |
2012-10-31 |
Sanofi |
Test Systems and methods for identifying a compound altering cellular DDR activity
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
GB201114858D0
(en)
|
2011-08-29 |
2011-10-12 |
Nvip Pty Ltd |
Anti-nerve growth factor antibodies and methods of using the same
|
HRP20211869T1
(hr)
|
2011-05-06 |
2022-03-04 |
Zoetis Services Llc |
Protutijela protiv faktora rasta živca i postupci za njihovu proizvodnju i uporabu
|
CA2835094C
(en)
|
2011-05-06 |
2020-12-22 |
David Gearing |
Anti-nerve growth factor antibodies and methods of preparing and using the same
|
KR101783929B1
(ko)
|
2011-05-06 |
2017-10-11 |
넥스베트 오스트레일리아 피티와이 리미티드 |
항신경성 성장 인자 항체 및 그의 제조방법과 이용방법
|
ES2704007T3
(es)
|
2011-05-06 |
2019-03-13 |
Nexvet Australia Pty Ltd |
Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
|
EP2707382B1
(en)
|
2011-05-09 |
2019-07-17 |
Ablynx NV |
Method for the production of immunoglobulin single variable domains
|
JP5987053B2
(ja)
|
2011-05-12 |
2016-09-06 |
ジェネンテック, インコーポレイテッド |
フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングlc−ms/ms法
|
AR090017A1
(es)
|
2011-05-16 |
2014-10-15 |
Genentech Inc |
Agonistas de fgfr1 y sus metodos de uso
|
MX358099B
(es)
|
2011-05-17 |
2018-08-06 |
Univ Rockefeller |
Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.
|
CN103857699B
(zh)
|
2011-05-24 |
2016-08-31 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
CN108329391A
(zh)
|
2011-05-27 |
2018-07-27 |
埃博灵克斯股份有限公司 |
使用rankl结合肽抑制骨质吸收
|
WO2012166906A1
(en)
|
2011-05-31 |
2012-12-06 |
Massachusetts Institute Of Technology |
Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
|
DK2718320T3
(en)
|
2011-06-10 |
2018-03-26 |
Medimmune Ltd |
ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF
|
WO2012171057A1
(en)
|
2011-06-13 |
2012-12-20 |
Csl Limited |
Antibodies against g-csfr and uses thereof
|
CN103596984B
(zh)
|
2011-06-15 |
2016-04-13 |
霍夫曼-拉罗奇有限公司 |
抗-人epo受体的抗体及使用方法
|
EP2537532A1
(en)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
|
EP4350345A2
(en)
|
2011-06-23 |
2024-04-10 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
|
EP2944654A1
(en)
|
2011-06-23 |
2015-11-18 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
|
US20180009888A9
(en)
|
2011-06-23 |
2018-01-11 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
JP2014525736A
(ja)
|
2011-06-23 |
2014-10-02 |
アブリンクス エン.ヴェー. |
IgEに対する免疫グロブリン単一可変ドメイン
|
RS55716B1
(sr)
|
2011-06-28 |
2017-07-31 |
Oxford Biotherapeutics Ltd |
Terapeutski i dijagnostički cilj
|
MY160826A
(en)
|
2011-06-28 |
2017-03-31 |
Berlin-Chemie Ag |
Antibodies to bone marrow stromal antigen 1
|
US20130004484A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
SG10201505454SA
(en)
|
2011-07-13 |
2015-09-29 |
Abbvie Inc |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
HUE038225T2
(hu)
|
2011-08-23 |
2018-10-29 |
Roche Glycart Ag |
Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák
|
US20130058937A1
(en)
|
2011-08-23 |
2013-03-07 |
Johannes Auer |
Bispecific antigen binding molecules
|
CA2844141A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
EP2751139A1
(en)
|
2011-08-30 |
2014-07-09 |
NVIP Pty Ltd |
Caninised tumour necrosis factor antibodies and methods of using the same
|
US9447192B2
(en)
|
2011-09-09 |
2016-09-20 |
Medimmune Limited |
Anti-Siglec-15 antibodies and uses thereof
|
EP2756005B1
(en)
|
2011-09-14 |
2016-03-02 |
Abeterno Technologies Limited |
Intracellular cell selection
|
MX2014003094A
(es)
|
2011-09-15 |
2014-04-25 |
Genentech Inc |
Metodos para promover diferenciacion.
|
AU2012311234B2
(en)
|
2011-09-19 |
2017-09-28 |
Axon Neuroscience Se |
Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease
|
GB201116116D0
(en)
|
2011-09-19 |
2011-11-02 |
Univ York |
Cell differentiation
|
SG11201400724SA
(en)
|
2011-09-19 |
2014-04-28 |
Genentech Inc |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
KR102007055B1
(ko)
|
2011-09-22 |
2019-08-02 |
암젠 인크 |
Cd27l 항원 결합 단백질
|
EP2747782B1
(en)
|
2011-09-23 |
2018-01-17 |
Ablynx NV |
Prolonged inhibition of interleukin-6 mediated signaling
|
GB201116702D0
(en)
|
2011-09-28 |
2011-11-09 |
Procure Therapeutics Ltd |
Cell surface markers
|
WO2013044298A1
(en)
|
2011-09-30 |
2013-04-04 |
Cephalon Australia Pty Ltd |
Antibodies against tl1a and uses thereof
|
MX2014004074A
(es)
|
2011-10-05 |
2014-06-05 |
Genentech Inc |
Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
|
US9575073B2
(en)
|
2011-10-10 |
2017-02-21 |
Rutgers, The State University Of New Jersey |
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
|
BR112014008862A2
(pt)
|
2011-10-14 |
2018-08-07 |
Genentech Inc |
anticorpo isolado que se liga à htra1, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, métodos e usos
|
CA2850836A1
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
RU2014120981A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Иммунные связывающие агенты против склеростина
|
KR20140084253A
(ko)
|
2011-10-24 |
2014-07-04 |
애브비 인코포레이티드 |
Tnf에 대한 면역결합제
|
MX2014004980A
(es)
|
2011-10-24 |
2014-09-11 |
Abbvie Inc |
Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17.
|
GB201118359D0
(en)
|
2011-10-25 |
2011-12-07 |
Univ Sheffield |
Pulmonary hypertension
|
WO2013063001A1
(en)
|
2011-10-28 |
2013-05-02 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
JP2015504413A
(ja)
|
2011-10-28 |
2015-02-12 |
パトリス リミテッド |
Pat−lm1エピトープおよびそれを使用するための方法
|
KR102037541B1
(ko)
|
2011-10-28 |
2019-10-29 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
폴리펩티드 구축물 및 이의 용도
|
GB201118840D0
(en)
|
2011-11-01 |
2011-12-14 |
Univ Sheffield |
Pulmonary hypertension II
|
EP3252075A1
(en)
|
2011-11-04 |
2017-12-06 |
Novartis AG |
Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
|
PL2773671T3
(pl)
|
2011-11-04 |
2022-01-24 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
|
CA2856216C
(en)
|
2011-11-11 |
2021-01-12 |
Ucb Pharma S.A. |
Albumin binding antibodies and binding fragments thereof
|
RU2014124842A
(ru)
|
2011-11-21 |
2015-12-27 |
Дженентек, Инк. |
Очистка анти-с-мет антител
|
CA2854042A1
(en)
|
2011-11-29 |
2013-06-06 |
Genentech, Inc. |
Compositions and methods for prostate cancer analysis
|
WO2013080050A2
(en)
|
2011-11-30 |
2013-06-06 |
Universitaetsklinikum Erlangen |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
WO2013084148A2
(en)
|
2011-12-05 |
2013-06-13 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
EA036739B1
(ru)
|
2011-12-05 |
2020-12-15 |
Новартис Аг |
Антитела к рецептору эпидермального фактора роста 3 (her3)
|
WO2013083497A1
(en)
|
2011-12-06 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
MX355624B
(es)
|
2011-12-22 |
2018-04-25 |
Hoffmann La Roche |
Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
|
SI2794878T1
(sl)
|
2011-12-22 |
2020-07-31 |
F. Hoffmann-La Roche Ag |
Organizacija ekspresijskega vektorja, postopki izdelave nove proizvodne celice in njihova uporaba za rekombinantno proizvodnjo polipeptidov
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
UY34558A
(es)
|
2011-12-30 |
2013-07-31 |
Abbvie Inc |
Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
|
CN104411717A
(zh)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
具有超长cdr3s的人源化抗体
|
AU2013208003B2
(en)
|
2012-01-09 |
2017-12-14 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
PL2802606T3
(pl)
|
2012-01-10 |
2018-09-28 |
Biogen Ma Inc. |
Udoskonalenie transportu cząsteczek terapeutycznych przez barierę krew-mózg
|
NZ626520A
(en)
|
2012-01-18 |
2016-09-30 |
Genentech Inc |
Anti-lrp5 antibodies and methods of use
|
RU2014133547A
(ru)
|
2012-01-18 |
2016-03-10 |
Дженентек, Инк. |
Способы применения модуляторов fgf19
|
IL305223A
(en)
|
2012-01-27 |
2023-10-01 |
Abbvie Inc |
The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
|
WO2013113641A1
(en)
|
2012-01-31 |
2013-08-08 |
Roche Glycart Ag |
Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
|
BR112014019579A2
(pt)
|
2012-02-10 |
2019-10-15 |
Genentech, Inc |
Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
|
AU2013216753B2
(en)
|
2012-02-11 |
2017-09-21 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
CA3159061A1
(en)
|
2012-02-15 |
2013-08-22 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203587D0
(en)
|
2012-03-01 |
2012-04-11 |
Univ Warwick |
Modified bacterial cell
|
BR112014018374A8
(pt)
|
2012-03-02 |
2017-07-11 |
Roche Glycart Ag |
Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
EP2831115A1
(en)
|
2012-03-27 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Diagnosis and treatments relating to her3 inhibitors
|
ES2678211T3
(es)
|
2012-03-27 |
2018-08-09 |
Ventana Medical Systems, Inc. |
Conjugados de señalización y procedimientos de uso
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
MX2014012889A
(es)
|
2012-05-01 |
2014-11-14 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-pmel17.
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
JP6351572B2
(ja)
|
2012-05-10 |
2018-07-04 |
ザイムワークス,インコーポレイテッド |
Fcドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
JP2015518829A
(ja)
|
2012-05-14 |
2015-07-06 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
運動ニューロンに関する状態の処置のためのlingo−2アンタゴニスト
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
EP2666786A1
(en)
|
2012-05-21 |
2013-11-27 |
PAION Deutschland GmbH |
Immunotherapy for intracranial hemorrhage
|
CA2870876C
(en)
|
2012-05-23 |
2019-10-01 |
Genentech, Inc. |
Selection method for therapeutic agents
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
JP5868549B2
(ja)
|
2012-05-24 |
2016-02-24 |
マウントゲイト グループ リミテッド |
狂犬病感染の予防および治療に関する組成物および方法
|
CA2875096A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
WO2014001326A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
|
CN104428006B
(zh)
|
2012-07-04 |
2017-09-08 |
弗·哈夫曼-拉罗切有限公司 |
共价连接的抗原‑抗体缀合物
|
CN104411725B
(zh)
|
2012-07-04 |
2018-09-28 |
弗·哈夫曼-拉罗切有限公司 |
抗生物素抗体及使用方法
|
EP3138578B1
(en)
|
2012-07-04 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Anti-theophylline antibodies and methods of use
|
SI2870247T1
(sl)
|
2012-07-05 |
2019-10-30 |
Hoffmann La Roche |
Ekspresijski in sekrecijski sistem
|
SG11201500096YA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti - cd79b antibodies
|
IN2014DN10652A
(ja)
|
2012-07-09 |
2015-09-11 |
Genentech Inc |
|
BR112015000441A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22
|
AR091701A1
(es)
|
2012-07-09 |
2015-02-25 |
Genentech Inc |
Anticuerpos anti-cd22 e inmunoconjugados
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
JP6154900B2
(ja)
|
2012-07-13 |
2017-06-28 |
ロシュ グリクアート アクチェンゲゼルシャフト |
二重特異性抗vegf/抗ang−2抗体及び眼血管疾患の処置におけるそれらの使用
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
MX365382B
(es)
|
2012-08-07 |
2019-05-31 |
Roche Glycart Ag |
Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
|
WO2014023673A1
(en)
|
2012-08-08 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-10 fusion proteins and uses thereof
|
MX2015001678A
(es)
|
2012-08-09 |
2015-08-14 |
Roche Glycart Ag |
Anticuerpos asgpr y sus usos.
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
KR20150064068A
(ko)
|
2012-10-08 |
2015-06-10 |
로슈 글리카트 아게 |
2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
|
IL301018A
(en)
|
2012-10-18 |
2023-05-01 |
Univ Rockefeller |
Broad-spectrum neutralizing antibodies against the AIDS virus
|
US9688741B2
(en)
|
2012-10-23 |
2017-06-27 |
Elastagen Pty Ltd |
Elastic hydrogel
|
AU2013337775B2
(en)
|
2012-11-01 |
2017-03-30 |
Abbvie Inc. |
Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
|
WO2014071358A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
CN104755500B
(zh)
|
2012-11-08 |
2020-10-02 |
霍夫曼-拉罗奇有限公司 |
结合HER3 β-发夹的HER3抗原结合蛋白
|
ES2701746T3
(es)
|
2012-11-13 |
2019-02-25 |
Hoffmann La Roche |
Anticuerpos antihemaglutinina y procedimientos de uso
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
CN105246520B
(zh)
|
2012-12-10 |
2017-11-21 |
埃拉斯塔根私人有限公司 |
可缩放的三维弹性构建体制造
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
EP2938637A2
(en)
|
2012-12-28 |
2015-11-04 |
AbbVie Inc. |
Multivalent binding protein compositions
|
EP2945652B1
(en)
|
2013-01-18 |
2021-07-07 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
EP2948177A1
(en)
|
2013-01-22 |
2015-12-02 |
AbbVie Inc. |
Methods for optimizing domain stability of binding proteins
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
WO2014114595A1
(en)
|
2013-01-23 |
2014-07-31 |
Roche Glycart Ag |
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
WO2014114801A1
(en)
|
2013-01-25 |
2014-07-31 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
KR102204127B1
(ko)
|
2013-02-01 |
2021-01-20 |
키라 바이오테크 피티와이 리미티드 |
항-cd83 항체 및 이의 용도
|
SG11201505762XA
(en)
|
2013-02-07 |
2015-08-28 |
Csl Ltd |
Il-11r binding proteins and uses thereof
|
US20140228875A1
(en)
|
2013-02-08 |
2014-08-14 |
Nidus Medical, Llc |
Surgical device with integrated visualization and cauterization
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
RU2015140921A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Антитела к mcsp
|
DK2961771T3
(da)
|
2013-02-26 |
2020-03-02 |
Roche Glycart Ag |
Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA
|
RU2015140917A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
EP3444278A1
(en)
|
2013-02-26 |
2019-02-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
JP6416793B2
(ja)
|
2013-02-28 |
2018-10-31 |
カプリオン プロテオミクス インコーポレーテッド |
結核のバイオマーカー及びその使用
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
BR112015022210A8
(pt)
|
2013-03-13 |
2018-01-23 |
Genentech Inc |
formulações de anticorpo
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
ES2843786T3
(es)
|
2013-03-13 |
2021-07-20 |
Seagen Inc |
Filtración con carbono activado para la purificación de ADC de benzodiazepina
|
MX370416B
(es)
|
2013-03-13 |
2019-12-10 |
Genentech Inc |
Formulaciones con oxidacion reducida.
|
JP6389236B2
(ja)
|
2013-03-13 |
2018-09-12 |
ジェネンテック, インコーポレイテッド |
酸化還元製剤
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
KR20150127199A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
항-b7-h4 항체 및 면역접합체
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
CN105307683A
(zh)
|
2013-03-14 |
2016-02-03 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
EP3916103A1
(en)
|
2013-03-14 |
2021-12-01 |
Abbott Laboratories |
Hcv core lipid binding domain monoclonal antibodies
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
BR112015023355A8
(pt)
|
2013-03-14 |
2018-01-30 |
Abbott Lab |
antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
|
CA2906421C
(en)
|
2013-03-14 |
2022-08-16 |
George J. Dawson |
Hcv antigen-antibody combination assay and methods and compositions for use therein
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
WO2014144850A1
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
RU2701378C2
(ru)
|
2013-03-15 |
2019-09-26 |
Дженентек, Инк. |
Биомаркеры и способы лечения связанных с pd-1 и pd-l1 состояний
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
RU2015144020A
(ru)
|
2013-03-15 |
2017-04-21 |
Дженентек, Инк. |
Среды для культивирования клеток и способы получения антител
|
CA2907181C
(en)
|
2013-03-15 |
2023-10-17 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
AU2014236769B2
(en)
|
2013-03-15 |
2018-09-27 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
AU2014228172B2
(en)
|
2013-03-15 |
2018-12-06 |
Abbvie Deutschland Gmbh & Co.Kg |
Anti-EGFR antibody drug conjugate formulations
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
AU2014240012A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Inc. |
Antibody drug conjugate (ADC) purification
|
CA2903852A1
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
KR102235452B1
(ko)
|
2013-03-15 |
2021-04-02 |
제넨테크, 인크. |
항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
|
BR112015020290A2
(pt)
|
2013-03-15 |
2017-10-10 |
Genentech Inc |
métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos
|
US9598485B2
(en)
|
2013-03-15 |
2017-03-21 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
GB201306589D0
(en)
|
2013-04-11 |
2013-05-29 |
Abeterno Ltd |
Live cell imaging
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
PT2992100T
(pt)
|
2013-04-29 |
2019-12-16 |
Agrosavfe Nv |
Composições agroquímicas compreendendo anticorpos que se ligam a esfingolípidos
|
EA033115B1
(ru)
|
2013-04-29 |
2019-08-30 |
Тева Фармасьютикалз Острэйлиа Пти Лтд. |
АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b
|
WO2014189973A2
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
PL3456743T3
(pl)
|
2013-05-30 |
2022-03-07 |
Kiniksa Pharmaceuticals, Ltd. |
Białka wiążące antygen receptora onkostatyny m
|
EP3022221B1
(en)
|
2013-07-18 |
2021-09-15 |
Taurus Biosciences, LLC |
Humanized antibodies with ultralong complementarity determining regions
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CU24312B1
(es)
|
2013-07-23 |
2018-02-08 |
Biocon Ltd |
Métodos para controlar los niveles de fucosilación en proteínas
|
CN106211774B
(zh)
|
2013-08-02 |
2020-11-06 |
辉瑞公司 |
抗cxcr4抗体及抗体-药物缀合物
|
BR112016003082A8
(pt)
|
2013-08-13 |
2020-01-28 |
Elastagen Pty Ltd |
uso da tropoelastina na produção de um medicamento para cicatrização de uma ferida ou para melhora da reepitelização de uma ferida
|
EP3046940B1
(en)
|
2013-09-17 |
2019-07-03 |
F.Hoffmann-La Roche Ag |
Methods of using anti-lgr5 antibodies
|
MY175472A
(en)
|
2013-09-27 |
2020-06-29 |
Genentech Inc |
Anti-pdl1 antibody formulations
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
SG11201602522VA
(en)
|
2013-10-02 |
2016-04-28 |
Medimmune Llc |
Neutralizing anti-influenza a antibodies and uses thereof
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
WO2015052230A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
RU2016117978A
(ru)
|
2013-10-11 |
2017-11-17 |
Дженентек, Инк. |
Ингибиторы nsp4 и способы их применения
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
RU2016114074A
(ru)
|
2013-10-18 |
2017-11-23 |
Дженентек, Инк. |
Анти-rspo антитела и способы применения
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
WO2015061441A1
(en)
|
2013-10-23 |
2015-04-30 |
Genentech, Inc. |
Methods of diagnosing and treating eosinophilic disorders
|
EP3069137A1
(en)
|
2013-11-05 |
2016-09-21 |
Novartis Ag |
Organic compounds
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
CN111499743B
(zh)
|
2013-11-21 |
2024-01-12 |
豪夫迈·罗氏有限公司 |
抗-α-突触核蛋白抗体及使用方法
|
JP6817064B2
(ja)
|
2013-11-27 |
2021-01-20 |
ザイムワークス,インコーポレイテッド |
Her2を標的とする二重特異性抗原結合性コンストラクト
|
ES2711882T3
(es)
|
2013-11-28 |
2019-05-08 |
B Creative Sweden Ab |
Método de tratamiento de la nefropatía diabética
|
WO2015084883A2
(en)
|
2013-12-02 |
2015-06-11 |
Abbvie, Inc. |
Compositions and methods for treating osteoarthritis
|
US9309314B2
(en)
|
2013-12-03 |
2016-04-12 |
Agency For Science, Technology And Research (A*Star) |
Polypeptides, nucleic acids and uses thereof
|
SG11201604632PA
(en)
|
2013-12-09 |
2016-07-28 |
Allakos Inc |
Anti-siglec-8 antibodies and methods of use thereof
|
AU2014362238A1
(en)
|
2013-12-13 |
2016-06-09 |
Genentech, Inc. |
Anti-CD33 antibodies and immunoconjugates
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
BR112016013741A2
(pt)
|
2013-12-17 |
2017-10-03 |
Genentech Inc |
Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
PL3192812T3
(pl)
|
2013-12-17 |
2020-10-19 |
Genentech, Inc. |
Przeciwciała anty-CD3 i sposoby ich zastosowania
|
KR20240017102A
(ko)
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
ES2851386T3
(es)
|
2013-12-18 |
2021-09-06 |
Csl Ltd |
Método de tratamiento de las heridas
|
SI3083680T1
(sl)
|
2013-12-20 |
2020-06-30 |
F. Hoffmann-La Roche Ag |
Humanizirana protitelesa proti beljakovini Tau(pS422) in postopki uporabe
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
CA2930046A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked polypeptide toxin-antibody conjugates
|
WO2015101587A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
|
US10561737B2
(en)
|
2014-01-03 |
2020-02-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
BR112016015589A2
(pt)
|
2014-01-06 |
2017-10-31 |
Hoffmann La Roche |
módulos de trânsito monovalentes para a barreira hematoencefálica
|
CA2936377A1
(en)
|
2014-01-10 |
2015-07-16 |
Shanghai Birdie Biotech, Inc. |
Compounds and compositions for treating egfr expressing tumors
|
AU2015209154A1
(en)
|
2014-01-24 |
2017-02-16 |
Genentech, Inc. |
Methods of using anti-STEAP1 antibodies and immunoconjugates
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
MX2016010237A
(es)
|
2014-02-08 |
2017-04-27 |
Genentech Inc |
Metodos de tratamiento de enfermedad de alzheimer.
|
RU2724190C2
(ru)
|
2014-02-08 |
2020-06-23 |
Дженентек, Инк. |
Способы лечения болезни альцгеймера
|
CR20160362A
(es)
|
2014-02-12 |
2016-09-20 |
Genentech Inc |
Anticuerpos anti-jagged1 y metodos de uso
|
AU2015218903B2
(en)
|
2014-02-20 |
2020-10-15 |
Allergan, Inc. |
Complement component C5 antibodies
|
KR20160124165A
(ko)
|
2014-02-21 |
2016-10-26 |
제넨테크, 인크. |
항-il-13/il-17 이중특이적 항체 및 그의 용도
|
KR20160126054A
(ko)
|
2014-02-27 |
2016-11-01 |
알러간, 인코포레이티드 |
보체 인자 Bb 항체
|
EP3110446B1
(en)
|
2014-02-28 |
2021-12-01 |
Allakos Inc. |
Methods and compositions for treating siglec-8 associated diseases
|
CA2941687A1
(en)
|
2014-03-14 |
2015-09-17 |
Genentech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
AR099812A1
(es)
|
2014-03-21 |
2016-08-17 |
Abbvie Inc |
Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
CN106132439A
(zh)
|
2014-03-31 |
2016-11-16 |
豪夫迈·罗氏有限公司 |
包含抗血管发生剂和ox40结合激动剂的组合疗法
|
EP3808778A1
(en)
|
2014-04-18 |
2021-04-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
RU2744836C2
(ru)
|
2014-05-08 |
2021-03-16 |
Новодиакс, Инк. |
Прямой иммуногистохимический анализ
|
CN106413750B
(zh)
|
2014-05-16 |
2022-04-29 |
免疫医疗有限责任公司 |
具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
|
CA2946662A1
(en)
|
2014-05-22 |
2015-11-26 |
Genentech, Inc. |
Anti-gpc3 antibodies and immunoconjugates
|
WO2015179835A2
(en)
|
2014-05-23 |
2015-11-26 |
Genentech, Inc. |
Mit biomarkers and methods using the same
|
WO2015191615A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
|
WO2015191617A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
|
WO2015191590A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
|
US11034757B2
(en)
|
2014-06-09 |
2021-06-15 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
|
US10758614B2
(en)
|
2014-06-09 |
2020-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health |
Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
|
WO2015191610A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
|
WO2015191596A1
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
|
CN106459202A
(zh)
|
2014-06-11 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
抗LgR5抗体及其用途
|
CA2951926C
(en)
|
2014-06-13 |
2023-01-10 |
Acceleron Pharma, Inc. |
Methods and compositions for treating ulcers
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
NL2013007B1
(en)
|
2014-06-16 |
2016-07-05 |
Ablynx Nv |
Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
BR112016029935A2
(pt)
|
2014-06-26 |
2017-10-31 |
Hoffmann La Roche |
?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
|
EP3680336A1
(en)
|
2014-07-03 |
2020-07-15 |
F. Hoffmann-La Roche AG |
Polypeptide expression systems
|
KR102462743B1
(ko)
|
2014-07-09 |
2022-11-02 |
버디 바이오파마슈티칼즈, 인크. |
종양 치료용 항-pd-l1 조합
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
US20160009805A1
(en)
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
CA2952315A1
(en)
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Notch pathway inhibition
|
JP6671363B2
(ja)
|
2014-07-15 |
2020-03-25 |
イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミティッド |
Cd44の単離されたポリペプチドおよびその使用
|
WO2016020309A1
(en)
|
2014-08-04 |
2016-02-11 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
RU2764074C2
(ru)
|
2014-08-28 |
2022-01-13 |
Байоатла, Ллк |
Условно активные химерные антигенные рецепторы для модифицированных т-клеток
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于***的抗-pd-l1结合物
|
CN106804108B
(zh)
|
2014-09-12 |
2021-08-10 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
DK3191135T3
(da)
|
2014-09-12 |
2020-10-12 |
Genentech Inc |
Anti-HER2-antistoffer og immunokonjugater
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
CN106794247B
(zh)
|
2014-09-15 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
抗体配制剂
|
JP6730261B2
(ja)
|
2014-09-17 |
2020-07-29 |
ジェネンテック, インコーポレイテッド |
抗her2抗体を含む免疫複合体
|
EP3689910A3
(en)
|
2014-09-23 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Method of using anti-cd79b immunoconjugates
|
RU2017115670A
(ru)
|
2014-10-10 |
2018-11-15 |
Аблинкс Н.В. |
Лечение инфекции рсв
|
EP3204095B8
(en)
|
2014-10-10 |
2019-07-10 |
Ablynx N.V. |
Inhalation device for use in aerosol therapy of respiratory diseases
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
US10584175B2
(en)
|
2014-10-23 |
2020-03-10 |
La Trobe University |
FN14-binding proteins and uses thereof
|
NZ731491A
(en)
|
2014-10-23 |
2021-12-24 |
Kira Biotech Pty Ltd |
Cd83 binding proteins and uses thereof
|
IL251822B2
(en)
|
2014-10-29 |
2023-03-01 |
Teva Pharmaceuticals Australia Pty Ltd |
Variants of interferon alpha-2-b
|
JP6691113B2
(ja)
|
2014-10-29 |
2020-04-28 |
シアトル ジェネティックス, インコーポレイテッド |
非フコシル化抗cd40抗体の投与量および投与
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
JP6702991B2
(ja)
|
2014-11-03 |
2020-06-03 |
ジェネンテック, インコーポレイテッド |
T細胞免疫サブセットを検出するためのアッセイ及びその使用の方法
|
US10066002B2
(en)
|
2014-11-05 |
2018-09-04 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
JP7089877B2
(ja)
|
2014-11-05 |
2022-06-23 |
バイオタリス・エン・フェー |
重鎖抗体の可変ドメインをコードするポリヌクレオチドを含むトランスジェニック植物
|
AU2015342961B2
(en)
|
2014-11-05 |
2021-08-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
RU2017119428A
(ru)
|
2014-11-06 |
2018-12-06 |
Дженентек, Инк. |
Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
EP3218403B1
(en)
|
2014-11-10 |
2020-05-13 |
F.Hoffmann-La Roche Ag |
Anti-interleukin-33 antibodies and uses thereof
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
MY191428A
(en)
|
2014-11-14 |
2022-06-27 |
Hoffmann La Roche |
Antigen binding molecules comprising a tnf family ligand trimer
|
SG10201807625PA
(en)
|
2014-11-17 |
2018-10-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US10434177B2
(en)
|
2014-11-17 |
2019-10-08 |
Carnegie Mellon University |
Activatable two-component photosensitizers
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法
|
CN107108745B
(zh)
|
2014-11-19 |
2021-01-12 |
基因泰克公司 |
抗bace1的抗体和其用于神经疾病免疫疗法的用途
|
RS61134B1
(sr)
|
2014-11-20 |
2020-12-31 |
Hoffmann La Roche |
Kombinovana terapija bispecifičnim antigen vezujućim molekulima koji aktiviraju t ćelije za cd3 i folatni receptor 1 (folr1), i antagonistima vezivanja ose pd-1
|
MX2017006626A
(es)
|
2014-11-20 |
2017-08-21 |
Hoffmann La Roche |
Cadenas ligeras comunes y metodos de uso.
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
SG11201704449VA
(en)
|
2014-12-05 |
2017-06-29 |
Genentech Inc |
ANTI-CD79b ANTIBODIES AND METHODS OF USE
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
PT3233910T
(pt)
|
2014-12-19 |
2020-03-17 |
Ablynx Nv |
Dímeros de nanocorpos ligados a cisteína
|
SG11201607165YA
(en)
|
2014-12-19 |
2016-09-29 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
US10940212B2
(en)
|
2014-12-19 |
2021-03-09 |
Monash University |
IL-21 agonist antibodies and methods of treatment using same
|
CA2973266A1
(en)
|
2015-01-08 |
2016-07-14 |
Biogen Ma Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
CN107427574B
(zh)
|
2015-01-09 |
2022-02-08 |
阿达尔塔有限公司 |
Cxcr4结合分子
|
CN107428823B
(zh)
|
2015-01-22 |
2021-10-26 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
US11304676B2
(en)
|
2015-01-23 |
2022-04-19 |
The University Of North Carolina At Chapel Hill |
Apparatuses, systems, and methods for preclinical ultrasound imaging of subjects
|
US10544210B2
(en)
|
2015-02-03 |
2020-01-28 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-Rho GTPase conformational single domain antibodies and uses thereof
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
TW202248212A
(zh)
|
2015-02-05 |
2022-12-16 |
日商中外製藥股份有限公司 |
包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
|
JP6724023B2
(ja)
|
2015-02-09 |
2020-07-15 |
リサーチ ディベロップメント ファウンデーション |
改善された補体活性化を示す操作された免疫グロブリンfcポリペプチド
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
WO2016149276A1
(en)
|
2015-03-16 |
2016-09-22 |
Genentech, Inc. |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
ES2863564T3
(es)
|
2015-04-06 |
2021-10-11 |
Acceleron Pharma Inc |
Heteromultímeros ALK7:ActRIIB y usos de los mismos
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
CN107709364A
(zh)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
具有激动剂活性的抗原结合复合体及使用方法
|
ES2899227T3
(es)
|
2015-04-07 |
2022-03-10 |
Alector Llc |
Anticuerpos anti sortilina y métodos de uso de los mismos
|
JP6815331B2
(ja)
|
2015-04-21 |
2021-01-20 |
ジェネンテック, インコーポレイテッド |
前立腺がんの分析のための組成物及び方法
|
PL3286315T3
(pl)
|
2015-04-24 |
2021-11-02 |
F. Hoffmann-La Roche Ag |
Sposoby identyfikacji bakterii zawierających polipeptydy wiążące
|
JP2018515082A
(ja)
|
2015-04-30 |
2018-06-14 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
代謝障害を処置するための抗ap2抗体及び抗原結合剤
|
JP2018520642A
(ja)
|
2015-05-01 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
マスク抗cd3抗体及びその使用方法
|
CN107592812A
(zh)
|
2015-05-11 |
2018-01-16 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
WO2016183326A1
(en)
|
2015-05-12 |
2016-11-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
EP3095465A1
(en)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Combination of fgfr4-inhibitor and bile acid sequestrant
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
CN107532217A
(zh)
|
2015-05-29 |
2018-01-02 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
CA2987051A1
(en)
|
2015-05-29 |
2016-12-08 |
Abbvie Inc. |
Anti-cd40 antibodies and uses thereof
|
US20180153884A1
(en)
|
2015-05-31 |
2018-06-07 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
CN107810012A
(zh)
|
2015-06-02 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗il‑34抗体治疗神经疾病的组合物和方法
|
TWI790642B
(zh)
|
2015-06-05 |
2023-01-21 |
美商建南德克公司 |
抗-tau抗體及使用方法
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
CA2988982A1
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
WO2016205176A1
(en)
|
2015-06-15 |
2016-12-22 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
IL256079B2
(en)
|
2015-06-16 |
2024-01-01 |
Genentech Inc |
Human antibodies with improved affinity to FCRH5 - and methods of use
|
JP2018526972A
(ja)
|
2015-06-16 |
2018-09-20 |
ジェネンテック, インコーポレイテッド |
抗cd3抗体及び使用方法
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
KR20180018538A
(ko)
|
2015-06-17 |
2018-02-21 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
CA2987797A1
(en)
|
2015-06-17 |
2016-12-22 |
Christopher Robert Bebbington |
Methods and compositions for treating fibrotic diseases
|
KR20180012859A
(ko)
|
2015-06-17 |
2018-02-06 |
제넨테크, 인크. |
항-her2 항체 및 이용 방법
|
CN113929779A
(zh)
|
2015-06-24 |
2022-01-14 |
豪夫迈·罗氏有限公司 |
人源化的抗-Tau(pS422)抗体和使用方法
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
CA3162816A1
(en)
|
2015-06-29 |
2017-01-05 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
WO2017004079A1
(en)
|
2015-06-29 |
2017-01-05 |
Biomed Valley Discoveries, Inc. |
Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment
|
EA201890158A1
(ru)
|
2015-06-30 |
2018-06-29 |
Сиэтл Дженетикс, Инк. |
Антитела против ntb-a и связанные композиции и способы
|
WO2017023866A1
(en)
|
2015-07-31 |
2017-02-09 |
Boston Biomedical, Inc. |
Method of targeting stat3 and other non-druggable proteins
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
KR20180035884A
(ko)
|
2015-08-04 |
2018-04-06 |
악셀레론 파마 인코포레이티드 |
골수증식성 장애를 치료하기 위한 방법
|
CN115960230A
(zh)
|
2015-08-07 |
2023-04-14 |
伊麦吉纳博公司 |
靶向分子的抗原结合构建体
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
WO2017040342A1
(en)
|
2015-08-28 |
2017-03-09 |
Genentech, Inc. |
Anti-hypusine antibodies and uses thereof
|
EP3350212A1
(en)
|
2015-09-18 |
2018-07-25 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
|
PE20181336A1
(es)
|
2015-09-18 |
2018-08-21 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ox40抗体及びその診断用途
|
TWI748962B
(zh)
|
2015-09-23 |
2021-12-11 |
美商建南德克公司 |
抗vegf抗體之最佳化變異體
|
MX2018003533A
(es)
|
2015-09-24 |
2019-04-25 |
Abvitro Llc |
Composiciones de anticuerpo de virus de inmunodeficiencia humana (vih) y metodos de uso.
|
KR20200087283A
(ko)
|
2015-09-25 |
2020-07-20 |
제넨테크, 인크. |
항-tigit 항체 및 이의 이용 방법
|
ES2839212T3
(es)
|
2015-09-29 |
2021-07-05 |
Inst Nat Sante Rech Med |
Métodos para determinar el estado metabólico de linfomas B
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
RS62450B1
(sr)
|
2015-10-02 |
2021-11-30 |
Hoffmann La Roche |
Anti-pd1 antitela i postupci primene
|
CN108026177B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗cd19xcd3 t细胞活化性抗原结合分子
|
AR106199A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas activadoras de células t
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
JP7044700B2
(ja)
|
2015-10-02 |
2022-03-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ceaxcd3 t細胞活性化抗原結合分子
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
EP3356417A1
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
JP7034066B2
(ja)
|
2015-10-02 |
2022-03-11 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体に対する二重特異性抗体
|
RU2018116402A
(ru)
|
2015-10-07 |
2019-11-07 |
Ф. Хоффманн-Ля Рош Аг |
Биспецифические антитела, четырехвалентные в отношении костимуляторного tnf-рецептора
|
US10556953B2
(en)
|
2015-10-12 |
2020-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
CN114891102A
(zh)
|
2015-10-29 |
2022-08-12 |
豪夫迈·罗氏有限公司 |
抗变体Fc区抗体及使用方法
|
JP2018534930A
(ja)
|
2015-10-30 |
2018-11-29 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体及びコンジュゲート
|
EP3368578B1
(en)
|
2015-10-30 |
2021-03-17 |
H. Hoffnabb-La Roche Ag |
Anti-htra1 antibodies and methods of use thereof
|
EP3371217A1
(en)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Methods of screening for multispecific antibodies
|
WO2017081190A1
(en)
|
2015-11-13 |
2017-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
JP7034913B2
(ja)
|
2015-11-20 |
2022-03-14 |
オースヴィル セラピューティクス ピーティーワイ リミテッド |
薬用化合物
|
EP3380121B1
(en)
|
2015-11-23 |
2023-12-20 |
Acceleron Pharma Inc. |
Actrii antagonist for use in treating eye disorders
|
RU2018122255A
(ru)
|
2015-11-27 |
2019-12-19 |
Аблинкс Нв |
Полипептиды, ингибирующие cd40l
|
CN115920030A
(zh)
|
2015-12-09 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于降低抗药物抗体形成
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
EP3390442B1
(en)
|
2015-12-18 |
2023-11-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antibodies and methods of use
|
MX2018007451A
(es)
|
2015-12-18 |
2018-11-09 |
Eisai R&D Man Co Ltd |
Inmunoglobulinas conjugadas con lisina c-terminal.
|
US10525137B2
(en)
|
2015-12-30 |
2020-01-07 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
AU2016381694A1
(en)
|
2015-12-30 |
2018-07-05 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
EP3400443B1
(en)
|
2016-01-04 |
2020-09-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
CN107531795B
(zh)
|
2016-01-05 |
2021-01-19 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
CN114019170A
(zh)
|
2016-01-20 |
2022-02-08 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
ES2924741T3
(es)
|
2016-01-28 |
2022-10-10 |
Inst Nat Sante Rech Med |
Métodos para incrementar la potencia de los inhibidores del punto de control inmunitario
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
EP4035681A1
(en)
|
2016-01-28 |
2022-08-03 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of cancer
|
EP3411396A1
(en)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
HUE054726T2
(hu)
|
2016-03-02 |
2021-09-28 |
Eisai R&D Man Co Ltd |
Eribulinalapú antitest-gyógyszer konjugátumok és alkalmazási eljárások
|
US11027021B2
(en)
|
2016-03-15 |
2021-06-08 |
Seagen Inc. |
Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
|
EP3430054B1
(en)
|
2016-03-15 |
2021-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
PL3433280T3
(pl)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
|
CR20180453A
(es)
|
2016-03-22 |
2018-12-05 |
Hoffmann La Roche |
Moleculas biespecíficas de células t activadas por proteasas
|
JP6943872B2
(ja)
|
2016-03-25 |
2021-10-06 |
ジェネンテック, インコーポレイテッド |
多重全抗体及び抗体複合体化薬物定量化アッセイ
|
EP3436477A2
(en)
|
2016-03-29 |
2019-02-06 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
WO2017174681A1
(en)
|
2016-04-06 |
2017-10-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
|
EP3443004A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3 antibodies and methods of use
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
PL3443350T3
(pl)
|
2016-04-15 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Sposoby monitorowania i leczenia nowotworu
|
WO2017182609A1
(en)
|
2016-04-22 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
|
WO2017189805A1
(en)
|
2016-04-27 |
2017-11-02 |
Abbvie Inc. |
Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
|
CA3022697A1
(en)
|
2016-05-02 |
2017-11-09 |
Ablynx Nv |
Treatment of rsv infection
|
PE20181890A1
(es)
|
2016-05-02 |
2018-12-11 |
Hoffmann La Roche |
Contorsbody - un ligante de diana monocatenario
|
WO2017191214A1
(en)
|
2016-05-03 |
2017-11-09 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Cd31shed as a molecular target for imaging of inflammation
|
ES2820173T3
(es)
|
2016-05-06 |
2021-04-19 |
Inst Nat Sante Rech Med |
Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
CN109071652B
(zh)
|
2016-05-11 |
2022-09-23 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
WO2017194441A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Modified anti-tenascin antibodies and methods of use
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
SI3455261T1
(sl)
|
2016-05-13 |
2023-01-31 |
Bioatla, Inc. |
Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
|
DK3458478T3
(da)
|
2016-05-18 |
2021-03-22 |
Boehringer Ingelheim Int |
Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
EP3463452A1
(en)
|
2016-05-24 |
2019-04-10 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
WO2017202890A1
(en)
|
2016-05-27 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating myeloma
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
JP2019521106A
(ja)
|
2016-06-08 |
2019-07-25 |
アッヴィ・インコーポレイテッド |
抗egfr抗体薬物コンジュゲート
|
EP3468599A2
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
EP3835322A3
(en)
|
2016-06-08 |
2021-10-06 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
MX2018015285A
(es)
|
2016-06-08 |
2019-09-18 |
Abbvie Inc |
Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
|
US20200002421A1
(en)
|
2016-06-08 |
2020-01-02 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
JP2019524651A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
AU2017277534A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-EGFR antibody drug conjugates
|
EP3468596A2
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
EP3468615A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-egfr antibody drug conjugates
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
JP7041077B2
(ja)
|
2016-06-10 |
2022-03-23 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
リジン結合体化免疫グロブリン
|
CN109563160B
(zh)
|
2016-06-24 |
2023-02-28 |
豪夫迈·罗氏有限公司 |
抗聚泛素多特异性抗体
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
RS62011B1
(sr)
|
2016-07-15 |
2021-07-30 |
Acceleron Pharma Inc |
Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije
|
US11618784B2
(en)
|
2016-07-19 |
2023-04-04 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-CD47 combination therapy
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
KR20190040972A
(ko)
|
2016-07-27 |
2019-04-19 |
악셀레론 파마 인코포레이티드 |
골섬유증 치료 방법 및 조성물
|
BR112019001693A2
(pt)
|
2016-07-29 |
2019-07-02 |
Ct Hospitalier Universitaire Toulouse |
anticorpos direcionados a macrófagos associados a tumores e seus usos
|
CN117986372A
(zh)
|
2016-07-29 |
2024-05-07 |
中外制药株式会社 |
显示增加的备选fviii辅因子功能活性的双特异性抗体
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
EP3494991A4
(en)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
CN109689111B
(zh)
|
2016-08-11 |
2024-04-05 |
基因泰克公司 |
吡咯并苯并二氮杂䓬前药及其抗体缀合物
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
US20190242908A1
(en)
|
2016-09-08 |
2019-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating nephrotic syndrome
|
EP3512880A1
(en)
|
2016-09-15 |
2019-07-24 |
Ablynx NV |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
HUE063135T2
(hu)
|
2016-09-23 |
2023-12-28 |
Hoffmann La Roche |
IL-13 antagonisták alkalmazásai atópiás dermatitis kezelésére
|
CN110023339A
(zh)
|
2016-09-23 |
2019-07-16 |
Csl有限公司 |
凝血因子结合蛋白及其应用
|
EP3519049A4
(en)
|
2016-09-30 |
2020-05-27 |
Janssen Biotech, Inc. |
SAFE AND EFFICIENT METHOD FOR TREATING PSORIASIS WITH ANTI-IL23-SPECIFIC ANTIBODY
|
ES2897217T3
(es)
|
2016-09-30 |
2022-02-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos frente a p95HER2
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
WO2018067879A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma Inc. |
Alk4:actriib heteromultimers and uses thereof
|
AU2017340504A1
(en)
|
2016-10-05 |
2019-04-11 |
Acceleron Pharma, Inc. |
Compositions and method for treating kidney disease
|
TWI775781B
(zh)
|
2016-10-06 |
2022-09-01 |
美商建南德克公司 |
癌症之治療性及診斷性方法
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
WO2018075564A1
(en)
|
2016-10-17 |
2018-04-26 |
University Of Maryland, College Park |
Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
|
EP3532496A1
(en)
|
2016-10-28 |
2019-09-04 |
Banyan Biomarkers, Inc. |
Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
WO2018087391A1
(en)
|
2016-11-14 |
2018-05-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
JP2020503260A
(ja)
|
2016-11-15 |
2020-01-30 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体による処置のための投与
|
WO2018093841A1
(en)
|
2016-11-16 |
2018-05-24 |
Janssen Biotech, Inc. |
Method of treating psoriasis with anti-il-23 specific antibody
|
CA3043515A1
(en)
|
2016-11-16 |
2018-05-24 |
Ablynx Nv |
T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
|
US20210277145A1
(en)
|
2016-11-17 |
2021-09-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for increasing endogenous protein level
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
US10899842B2
(en)
|
2016-11-23 |
2021-01-26 |
Immunoah Therapeutics, Inc. |
4-1BB binding proteins and uses thereof
|
EP3546574A4
(en)
|
2016-11-28 |
2020-09-09 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN AND POLYPEPTIDE BINDING AREA INCLUDING A TRANSPORT SECTION
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
WO2018100190A1
(en)
|
2016-12-02 |
2018-06-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
KR20230146126A
(ko)
|
2016-12-07 |
2023-10-18 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
CN110248959B
(zh)
|
2016-12-07 |
2023-06-30 |
基因泰克公司 |
抗tau抗体和使用方法
|
EP3555620A1
(en)
|
2016-12-13 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
WO2018112474A1
(en)
|
2016-12-16 |
2018-06-21 |
Merck Patent Gmbh |
Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis
|
TWI829628B
(zh)
|
2016-12-19 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
與靶向4-1bb (cd137)促效劑併用之組合療法
|
BR112019007267A2
(pt)
|
2016-12-20 |
2019-07-09 |
Hoffmann La Roche |
anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
|
GB201621806D0
(en)
|
2016-12-21 |
2017-02-01 |
Philogen Spa |
Immunocytokines with progressive activation mechanism
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
CN108261544B
(zh)
|
2016-12-30 |
2023-05-05 |
江苏太平洋美诺克生物药业股份有限公司 |
稳定的包含cd147单克隆抗体的药物制剂
|
CN108261391B
(zh)
|
2016-12-30 |
2022-03-01 |
江苏太平洋美诺克生物药业有限公司 |
稳定的包含cd147单克隆抗体的药物制剂
|
MA47200A
(fr)
|
2017-01-03 |
2019-11-13 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb
|
WO2018134389A1
(en)
|
2017-01-23 |
2018-07-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating infections
|
CN110234351A
(zh)
|
2017-01-30 |
2019-09-13 |
詹森生物科技公司 |
用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
|
EP3576789A4
(en)
|
2017-02-01 |
2020-11-25 |
Centrymed Pharmaceuticals Inc. |
MONOMER HUMAN IGG1-FC AND BISPECIFIC ANTIBODIES
|
CN110418652A
(zh)
|
2017-02-07 |
2019-11-05 |
詹森生物科技公司 |
用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
RU2771485C2
(ru)
|
2017-02-10 |
2022-05-04 |
Дженентек, Инк. |
Антитела против триптазы, их композиции и применения
|
EP3579872A1
(en)
|
2017-02-10 |
2019-12-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
WO2018158335A1
(en)
|
2017-02-28 |
2018-09-07 |
Vib Vzw |
Means and methods for oral protein delivery
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
CN110392697A
(zh)
|
2017-03-02 |
2019-10-29 |
国家医疗保健研究所 |
对nectin-4具有特异性的抗体及其用途
|
WO2018175752A1
(en)
|
2017-03-22 |
2018-09-27 |
Genentech, Inc. |
Optimized antibody compositions for treatment of ocular disorders
|
JP7216006B2
(ja)
|
2017-03-22 |
2023-01-31 |
ジェネンテック, インコーポレイテッド |
ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
|
US20210186982A1
(en)
|
2017-03-24 |
2021-06-24 |
Universite Nice Sophia Antipolis |
Methods and compositions for treating melanoma
|
WO2018178030A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
RU2019133202A
(ru)
|
2017-03-27 |
2021-04-28 |
Ф. Хоффманн-Ля Рош Аг |
Улучшенные антигенсвязывающие рецепторы
|
WO2018178029A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
WO2018177967A1
(en)
|
2017-03-27 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptor formats
|
TW201836640A
(zh)
|
2017-03-28 |
2018-10-16 |
美商建南德克公司 |
治療神經退化性疾病之方法
|
EP3601325B1
(en)
|
2017-03-28 |
2023-07-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New tau species
|
EP3601346A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
WO2018178055A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
CN110709106A
(zh)
|
2017-03-30 |
2020-01-17 |
杜克大学 |
放射性标记的生物分子及其应用
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
WO2018184965A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
CN110494452B
(zh)
|
2017-04-03 |
2023-08-25 |
豪夫迈·罗氏有限公司 |
结合steap-1的抗体
|
BR112019017753A2
(pt)
|
2017-04-04 |
2020-04-07 |
Hoffmann La Roche |
molécula biespecífica, polinucleotídeo, vetor, célula, métodos para a produção de uma molécula e para o tratamento de um indivíduo, composição e uso da molécula biespecífica
|
MX2019011916A
(es)
|
2017-04-05 |
2020-01-09 |
Hoffmann La Roche |
Anticuerpos anti-lag3.
|
KR102346336B1
(ko)
|
2017-04-05 |
2022-01-04 |
에프. 호프만-라 로슈 아게 |
Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
US20200033347A1
(en)
|
2017-04-18 |
2020-01-30 |
Universite Libre De Bruxelles |
Biomarkers And Targets For Proliferative Diseases
|
CA3064697A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
PE20200150A1
(es)
|
2017-04-21 |
2020-01-17 |
Genentech Inc |
Uso de antagonistas de klk5 para el tratamiento de una enfermedad
|
BR112019022515A2
(pt)
|
2017-04-27 |
2020-06-16 |
Tesaro, Inc. |
Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos
|
AU2018261887A1
(en)
|
2017-05-05 |
2019-12-05 |
Allakos Inc. |
Methods and compositions for treating allergic ocular diseases
|
WO2018206734A1
(en)
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
CN111094335B
(zh)
|
2017-05-15 |
2022-08-23 |
罗切斯特大学 |
广泛中和的抗流感单克隆抗体及其用途
|
EP3403649A1
(en)
|
2017-05-16 |
2018-11-21 |
Bayer Pharma Aktiengesellschaft |
Inhibitors and antagonists of gpr84 for the treatment of endometriosis
|
KR20200013683A
(ko)
|
2017-05-17 |
2020-02-07 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
오피오이드에 의한 통증 치료 개선용 flt3 저해제
|
TWI714854B
(zh)
*
|
2017-05-24 |
2021-01-01 |
財團法人生物技術開發中心 |
抗globo h之人類化抗體及其於治療癌症之用途
|
EP3406253A1
(en)
|
2017-05-24 |
2018-11-28 |
Bayer Aktiengesellschaft |
Inhibitors and antagonists of human pycr1
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
EP3630818A1
(en)
|
2017-06-02 |
2020-04-08 |
Ablynx NV |
Aggrecan binding immunoglobulins
|
CA3064469A1
(en)
|
2017-06-02 |
2018-12-06 |
Merck Patent Gmbh |
Mmp13 binding immunoglobulins
|
MX2019014400A
(es)
|
2017-06-02 |
2020-02-10 |
Merck Patent Gmbh |
Inmunoglobulinas que se unen a adamts.
|
MX2019014274A
(es)
|
2017-06-02 |
2020-01-23 |
Hoffmann La Roche |
Metodo de tratamiento.
|
MX2019014397A
(es)
|
2017-06-02 |
2020-02-10 |
Merck Patent Gmbh |
Polipeptidos que enlazan adamts5, mmp13 y agrecano.
|
US20210079100A1
(en)
|
2017-06-08 |
2021-03-18 |
Inserm (Institute National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating hyperpigmentation disorders
|
EP3635398A1
(en)
|
2017-06-08 |
2020-04-15 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Chimeric receptor for use in whole-cell sensors for detecting analytes of interest
|
JP7264831B2
(ja)
*
|
2017-06-15 |
2023-04-25 |
ディベロップメント センター フォー バイオテクノロジー |
抗globo h抗体を含有する抗体-薬物コンジュゲートおよびその使用
|
EP3641802A1
(en)
|
2017-06-22 |
2020-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
WO2019002548A1
(en)
|
2017-06-29 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
|
PE20200757A1
(es)
|
2017-07-11 |
2020-07-27 |
Compass Therapeutics Llc |
Anticuerpos agonistas que se unen a cd137 humano y sus usos
|
KR102625929B1
(ko)
|
2017-07-19 |
2024-01-16 |
브이아이비 브이지더블유 |
혈청 알부민 결합제
|
WO2019016310A1
(en)
|
2017-07-20 |
2019-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND COMPOSITIONS FOR TREATING CANCERS
|
WO2019018757A1
(en)
|
2017-07-21 |
2019-01-24 |
Genentech, Inc. |
THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
|
US11174322B2
(en)
|
2017-07-24 |
2021-11-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies and peptides to treat HCMV related diseases
|
EP3658173A1
(en)
|
2017-07-25 |
2020-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
CN110869050A
(zh)
|
2017-07-28 |
2020-03-06 |
豪夫迈·罗氏有限公司 |
双特异性抗体配制剂
|
KR20200033798A
(ko)
|
2017-08-03 |
2020-03-30 |
알렉터 엘엘씨 |
항-cd33 항체 및 이의 이용 방법
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
ANTI-CD137 MOLECULES AND THEIR USE
|
EP3676296A1
(en)
|
2017-08-30 |
2020-07-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-mesothelin radiolabelled single domain antibodies suitable for the imaging and treatment of cancers
|
EP3457139A1
(en)
|
2017-09-19 |
2019-03-20 |
Promise Advanced Proteomics |
Antibody-like peptides for quantifying therapeutic antibodies
|
US20200216542A1
(en)
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
JP7330174B2
(ja)
|
2017-09-20 |
2023-08-21 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
オートファジーをモジュレーションするための方法及び医薬組成物
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
CN111246885A
(zh)
|
2017-10-20 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
从单特异性抗体生成多特异性抗体的方法
|
WO2019081456A1
(en)
|
2017-10-24 |
2019-05-02 |
Bayer Aktiengesellschaft |
USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
|
TWI832824B
(zh)
|
2017-10-30 |
2024-02-21 |
瑞士商赫孚孟拉羅股份公司 |
自單特異性抗體於活體內產生多特異性抗體之方法
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
US11873347B2
(en)
|
2017-10-31 |
2024-01-16 |
Vib Vzw |
Antigen-binding chimeric proteins and methods and uses thereof
|
PE20210844A1
(es)
|
2017-11-01 |
2021-05-10 |
Hoffmann La Roche |
Contorsbodies 2 + biespecificos
|
EP3704150A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
The compbody - a multivalent target binder
|
CN111246884A
(zh)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
新颖的含有tnf家族配体三聚体的抗原结合分子
|
KR20200084006A
(ko)
|
2017-11-01 |
2020-07-09 |
에프. 호프만-라 로슈 아게 |
표적화된 ox40 작용제를 사용하는 병용 요법
|
JP2021502066A
(ja)
|
2017-11-06 |
2021-01-28 |
ジェネンテック, インコーポレイテッド |
がんの診断及び療法
|
CA3082365A1
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
US11787874B2
(en)
|
2017-11-15 |
2023-10-17 |
Novo Nordisk A/S |
Factor X binders enhancing FX activation
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
WO2019101995A1
(en)
|
2017-11-27 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for cardiac regeneration
|
CA3083259A1
(en)
|
2017-11-28 |
2019-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide including antigen-binding domain and carrying section
|
BR112020010514A2
(pt)
|
2017-11-29 |
2020-11-24 |
Csl Limited |
método para tratar ou prevenir lesão por isquemia-reperfusão
|
EP3717515A2
(en)
|
2017-12-01 |
2020-10-07 |
Seattle Genetics, Inc. |
Cd47 (masked) antibodies and uses thereof for treating cancer
|
KR20200090838A
(ko)
|
2017-12-01 |
2020-07-29 |
시애틀 지네틱스, 인크. |
유방암 치료를 위한 인간화된 항-liv1 항체
|
TW201934578A
(zh)
|
2017-12-14 |
2019-09-01 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
AU2018388791A1
(en)
|
2017-12-19 |
2020-07-16 |
The Rockefeller University |
Human IgG Fc domain variants with improved effector function
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
WO2019122046A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Universal reporter cell assay for specificity test of novel antigen binding moieties
|
CN111492243A
(zh)
|
2017-12-21 |
2020-08-04 |
豪夫迈·罗氏有限公司 |
用于新颖抗原结合模块的特异性测试的car-t细胞测定法
|
TWI805665B
(zh)
|
2017-12-21 |
2023-06-21 |
瑞士商赫孚孟拉羅股份公司 |
結合hla-a2/wt1之抗體
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
CA3082280A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against tigit
|
CN111886246A
(zh)
|
2017-12-29 |
2020-11-03 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
WO2019134946A1
(en)
|
2018-01-04 |
2019-07-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
EP3740507A4
(en)
|
2018-01-15 |
2022-08-24 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
JP2021510594A
(ja)
|
2018-01-25 |
2021-04-30 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
臓器の虚血再灌流傷害を予防する方法における使用のためのil−33のアンタゴニスト
|
WO2019149715A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Stabilized immunoglobulin domains
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
CN111971301A
(zh)
|
2018-01-31 |
2020-11-20 |
艾莱克特有限责任公司 |
抗ms4a4a抗体及其使用方法
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
JP2021512947A
(ja)
|
2018-02-06 |
2021-05-20 |
アブリンクス・エヌ・フェー |
Ttpの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法
|
JP7475275B2
(ja)
|
2018-02-08 |
2024-04-26 |
ジェネンテック, インコーポレイテッド |
二重特異性抗原結合分子及びその使用方法
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
CA3088557C
(en)
|
2018-02-09 |
2024-02-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
CA3091311A1
(en)
|
2018-02-16 |
2019-08-22 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Use of antagonists of cxcr3b for treating vitiligo
|
US20200399376A1
(en)
|
2018-02-26 |
2020-12-24 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CA3092421A1
(en)
|
2018-03-01 |
2019-09-06 |
Vrije Universiteit Brussel |
Human pd-l1-binding immunoglobulins
|
EP3759491A1
(en)
|
2018-03-01 |
2021-01-06 |
H. Hoffnabb-La Roche Ag |
Specificity assay for novel target antigen binding moieties
|
KR20200129125A
(ko)
|
2018-03-05 |
2020-11-17 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 크론병을 치료하는 방법
|
CN111655731A
(zh)
|
2018-03-13 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
KR20200132913A
(ko)
|
2018-03-13 |
2020-11-25 |
에프. 호프만-라 로슈 아게 |
4-1bb 작용제와 항-cd20 항체의 치료 조합
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
BR112020014591A2
(pt)
|
2018-03-14 |
2020-12-01 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
anticorpos anticlaudina 18.2
|
TWI827585B
(zh)
|
2018-03-15 |
2024-01-01 |
日商中外製藥股份有限公司 |
對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
|
US11661452B2
(en)
|
2018-03-20 |
2023-05-30 |
WuXi Biologics Ireland Limited |
Anti-lag-3 antibody polypeptide
|
KR20200133376A
(ko)
|
2018-03-21 |
2020-11-27 |
알렉소 온콜로지 인크. |
신호-조절 단백질 알파에 대한 항체 및 사용 방법
|
PL3768701T3
(pl)
|
2018-03-23 |
2024-02-19 |
Université Libre de Bruxelles |
Cząsteczki agonistów sygnalizacji WNT
|
WO2019191552A1
(en)
|
2018-03-29 |
2019-10-03 |
Genentech, Inc. |
Modulating lactogenic activity in mammalian cells
|
WO2019185040A1
(en)
|
2018-03-30 |
2019-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against lag-3 and uses thereof
|
WO2019192432A1
(zh)
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
WO2019192973A1
(en)
|
2018-04-04 |
2019-10-10 |
F. Hoffmann-La Roche Ag |
Diagnostic assays to detect tumor antigens in cancer patients
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
CN112424601A
(zh)
|
2018-04-04 |
2021-02-26 |
豪夫迈·罗氏有限公司 |
检测癌症患者中肿瘤抗原的诊断性测定法
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
KR20200144114A
(ko)
|
2018-04-13 |
2020-12-28 |
에프. 호프만-라 로슈 아게 |
4-1bbl을 포함하는 her-2 표적화 항원 결합 분자
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
JP7402541B2
(ja)
|
2018-05-03 |
2023-12-21 |
ユニバーシティ オブ ロチェスター |
抗インフルエンザノイラミニダーゼモノクローナル抗体およびその使用
|
CA3100007A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
JP2021523741A
(ja)
|
2018-05-14 |
2021-09-09 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
活性化可能なインターロイキン12ポリペプチド及びその使用方法
|
MX2020012378A
(es)
|
2018-05-18 |
2021-02-09 |
Hoffmann La Roche |
Administracion intracelular dirigida de acidos nucleicos grandes.
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
MA52753A
(fr)
|
2018-05-25 |
2021-04-21 |
Alector Llc |
Anticorps anti-sirpa et leurs procédés d'utilisation
|
US20210253672A1
(en)
|
2018-05-30 |
2021-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule containing single domain antibody
|
CN112367996A
(zh)
|
2018-06-01 |
2021-02-12 |
卫材R&D管理有限公司 |
使用剪接调节剂的方法
|
JP7390315B2
(ja)
|
2018-06-01 |
2023-12-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
|
EP3801613A1
(en)
|
2018-06-04 |
2021-04-14 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
EP3805400A4
(en)
|
2018-06-04 |
2022-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule showing changed half-life in cytoplasm
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
CA3103629A1
(en)
|
2018-06-15 |
2019-12-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
EP3810653A1
(en)
|
2018-06-23 |
2021-04-28 |
F. Hoffmann-La Roche AG |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
JP2021529520A
(ja)
|
2018-06-29 |
2021-11-04 |
アレクトル エルエルシー |
抗sirp−ベータ1抗体及びその使用方法
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
CN112424228A
(zh)
|
2018-07-04 |
2021-02-26 |
豪夫迈·罗氏有限公司 |
新型双特异性激动性4-1bb抗原结合分子
|
WO2020008083A1
(es)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
|
KR20230065382A
(ko)
|
2018-07-13 |
2023-05-11 |
알렉터 엘엘씨 |
항-소틸린 항체 및 이들의 사용 방법
|
JP2021530697A
(ja)
|
2018-07-18 |
2021-11-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体で治療した後の持続応答予測因子
|
AU2019305637A1
(en)
|
2018-07-18 |
2021-03-11 |
Genentech, Inc. |
Methods of treating lung cancer with a PD-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
CA3106114A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
CN113286819A
(zh)
|
2018-08-01 |
2021-08-20 |
感应检查疗法公司 |
抗btn3a抗体及其在治疗癌症或感染性病症中的用途
|
SG11202101152QA
(en)
|
2018-08-03 |
2021-03-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
JP2021533149A
(ja)
|
2018-08-08 |
2021-12-02 |
ジェネンテック, インコーポレイテッド |
タンパク質製剤のためのトリプトファン誘導体及びl−メチオニンの使用
|
KR102259473B1
(ko)
|
2018-08-10 |
2021-06-02 |
추가이 세이야쿠 가부시키가이샤 |
항cd137 항원 결합 분자 및 그의 사용
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
US11548938B2
(en)
|
2018-08-21 |
2023-01-10 |
Quidel Corporation |
DbpA antibodies and uses thereof
|
SG11202101552SA
(en)
|
2018-08-31 |
2021-03-30 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
WO2020049026A1
(en)
|
2018-09-05 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating asthma and allergic diseases
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
US20220048995A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof
|
EP3849602A1
(en)
|
2018-09-10 |
2021-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
WO2020053125A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
WO2020058201A1
(en)
|
2018-09-17 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of phosphatase activity of soluble epoxide for the treatment of cardiometabolic diseases
|
AR114732A1
(es)
|
2018-09-18 |
2020-10-07 |
Hoffmann La Roche |
Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
|
CN113396160A
(zh)
|
2018-09-19 |
2021-09-14 |
国家医疗保健研究所 |
治疗对免疫检查点疗法具有抗性的癌症的方法和药物组合物
|
JP2022501332A
(ja)
|
2018-09-19 |
2022-01-06 |
ジェネンテック, インコーポレイテッド |
膀胱がんの治療方法および診断方法
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
KR20230148273A
(ko)
|
2018-09-24 |
2023-10-24 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법
|
US20220033486A1
(en)
|
2018-09-25 |
2022-02-03 |
Inserm (Institut National De La Santè Et De La Recherch Médicale) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
MX2021003543A
(es)
|
2018-09-27 |
2021-06-23 |
Xilio Dev Inc |
Polipeptidos de citocinas enmascaradas.
|
WO2020070035A1
(en)
|
2018-10-01 |
2020-04-09 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules with trivalent binding to cd40
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
CA3113548A1
(en)
|
2018-10-01 |
2020-04-09 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-fap clone 212
|
US20210340278A1
(en)
|
2018-10-04 |
2021-11-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases
|
WO2020070288A1
(en)
|
2018-10-05 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
EP3636657A1
(en)
|
2018-10-08 |
2020-04-15 |
Ablynx N.V. |
Chromatography-free antibody purification method
|
US20210347898A1
(en)
|
2018-10-09 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
|
US20200109200A1
(en)
|
2018-10-09 |
2020-04-09 |
Genentech, Inc. |
Methods and systems for determining synapse formation
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
JP2022512744A
(ja)
|
2018-10-18 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
肉腫様腎臓がんのための診断および治療方法
|
WO2020079162A1
(en)
|
2018-10-18 |
2020-04-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for inducing full ablation of hematopoiesis
|
AU2019365238A1
(en)
|
2018-10-24 |
2021-05-13 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
CA3117051A1
(en)
|
2018-11-05 |
2020-05-14 |
Genentech, Inc. |
Methods of producing two chain proteins in prokaryotic host cells
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
US20220332800A1
(en)
|
2018-11-20 |
2022-10-20 |
Takeda Vaccines, Inc. |
Novel anti-zika virus antibodies and uses thereof
|
MA55149A
(fr)
|
2018-11-20 |
2021-09-29 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
AU2019397062A1
(en)
|
2018-12-13 |
2021-05-06 |
Eisai R&D Management Co., Ltd. |
Herboxidiene antibody-drug conjugates and methods of use
|
US20220017611A1
(en)
|
2018-12-13 |
2022-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New anti tau svqivykpv epitope single domain antibody
|
US20200197517A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
PE20211295A1
(es)
|
2018-12-21 |
2021-07-20 |
23Andme Inc |
Anticuerpos anti il-36 y procedimientos de uso de estos
|
SG10202105788SA
(en)
|
2018-12-21 |
2021-06-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
AU2019410073A1
(en)
|
2018-12-21 |
2021-06-10 |
F. Hoffmann-La Roche Ag |
Tumor-targeted agonistic CD28 antigen binding molecules
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
TW202030204A
(zh)
|
2018-12-21 |
2020-08-16 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之超促效cd28抗原結合分子
|
JP2022514082A
(ja)
|
2018-12-21 |
2022-02-09 |
ジェネンテック, インコーポレイテッド |
アポトーシスに耐性のある細胞株を使用してポリペプチドを生成する方法
|
EA202191784A1
(ru)
|
2018-12-26 |
2021-10-20 |
Сити Оф Хоуп |
Активируемые маскированные связывающие белки к ctla4
|
EP3902830A1
(en)
|
2018-12-30 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Anti-rabbit cd19 antibodies and methods of use
|
MX2021008121A
(es)
|
2019-01-03 |
2021-12-10 |
Inst Nat Sante Rech Med |
Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
|
AU2020208193A1
(en)
|
2019-01-14 |
2021-07-29 |
BioNTech SE |
Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
|
JP2022518208A
(ja)
|
2019-01-15 |
2022-03-14 |
ヤンセン バイオテツク,インコーポレーテツド |
若年性特発性関節炎の治療のための抗tnf抗体、組成物、及び方法
|
WO2020152544A1
(en)
|
2019-01-23 |
2020-07-30 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
|
BR112021014481A2
(pt)
|
2019-01-23 |
2021-10-13 |
Genentech, Inc. |
Método para produzir um polipeptídeo multimérico, método para produzir um anticorpo biespecífico, pluralidade de polipeptídeos multiméricos, células hospedeiras eucarióticas recombinantes, método para identificar uma combinação de sequências e kit de polinucleotídeos
|
US20220089770A1
(en)
|
2019-01-24 |
2022-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Novel cancer antigens and antibodies of said antigens
|
EP3917957A1
(en)
|
2019-01-28 |
2021-12-08 |
Maple Biotech LLC |
Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
WO2020161083A1
(en)
|
2019-02-04 |
2020-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
JP2022519649A
(ja)
|
2019-02-08 |
2022-03-24 |
ジェネンテック, インコーポレイテッド |
がんの診断および治療方法
|
KR102398485B1
(ko)
|
2019-02-18 |
2022-05-16 |
에이티비 테라퓨틱스 |
식물 세포 또는 식물 전체에서 결합제-독소 융합 단백질의 생산 방법
|
WO2020169698A1
(en)
|
2019-02-21 |
2020-08-27 |
F. Hoffmann-La Roche Ag |
Sensitization of cancer cells to tnf by bet inhibition
|
WO2020169707A1
(en)
|
2019-02-21 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Foxo1 inhibitor for use in the treatment of latent virus infection
|
BR112021016923A2
(pt)
|
2019-02-27 |
2021-11-03 |
Genentech Inc |
Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
|
PE20220495A1
(es)
|
2019-03-01 |
2022-04-07 |
Allogene Therapeutics Inc |
Receptores antigenicos quimericos y agentes de union dirigidos a dll3
|
US20220137054A1
(en)
|
2019-03-05 |
2022-05-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New biomarkers and biotargets in renal cell carcinoma
|
JP7402247B2
(ja)
|
2019-03-08 |
2023-12-20 |
ジェネンテック, インコーポレイテッド |
細胞外小胞の膜結合タンパク質を検出及び定量化するための方法
|
KR20210142002A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생성하기 위한 제조 방법
|
MA55283A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de production de compositions d'anticorps anti-tnf
|
CA3133388A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
CN113825765A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
CR20210467A
(es)
|
2019-03-14 |
2021-10-07 |
Genentech Inc |
Tratamiento de cáncer con anticuerpos biespecíficos contra her2xcd3 en combinación con mab anti-her2
|
CA3199205A1
(en)
|
2019-03-15 |
2020-09-24 |
Cartesian Therapeutics, Inc. |
Anti-bcma chimeric antigen receptors
|
EA202192459A1
(ru)
|
2019-03-18 |
2021-11-25 |
Янссен Байотек, Инк. |
Способ лечения псориаза антителом к il12/il23 у субъектов детского возраста
|
EP3943108A4
(en)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
|
EP3947446A1
(en)
|
2019-03-25 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of taupathy disorders by targeting new tau species
|
WO2020201073A1
(en)
|
2019-03-29 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
BR112021019365A2
(pt)
|
2019-03-29 |
2021-11-30 |
Genentech Inc |
Métodos para identificar um indivíduo que tem câncer, para selecionar uma terapia, para identificar uma interação proteína-proteína e para identificar um modulador, métodos de tratamento de um indivíduo com câncer, de identificação, de seleção de uma terapia e de identificação de um modulador, coleções de polipeptídeos, de vetores e de células e moduladores isolados
|
EP3947737A2
(en)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
EP3946377A1
(en)
|
2019-04-03 |
2022-02-09 |
Orega Biotech |
Combination therapies based on pd1 and il-17b inhibitors
|
EP3946416A2
(en)
|
2019-04-04 |
2022-02-09 |
Bayer Aktiengesellschaft |
Agonists of adiponectin
|
SG11202109901TA
(en)
|
2019-04-09 |
2021-10-28 |
Hospital For Special Surgery |
Protein binders for irhom2
|
EP3952996A1
(en)
|
2019-04-12 |
2022-02-16 |
F. Hoffmann-La Roche AG |
Bispecific antigen binding molecules comprising lipocalin muteins
|
JP2022527565A
(ja)
|
2019-04-12 |
2022-06-02 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
CEA CD3二重特異性抗体及びWntシグナル伝達阻害剤を使用するがんの治療
|
CA3134522A1
(en)
|
2019-04-19 |
2020-10-22 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
CN113748201A
(zh)
|
2019-04-26 |
2021-12-03 |
艾洛基治疗公司 |
制备同种异体car t细胞的方法
|
WO2020221796A1
(en)
|
2019-04-30 |
2020-11-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
CA3133821A1
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
SG11202112541RA
(en)
|
2019-05-14 |
2021-12-30 |
Werewolf Therapeutics Inc |
Separation moieties and methods and use thereof
|
TW202108178A
(zh)
|
2019-05-14 |
2021-03-01 |
美商建南德克公司 |
使用抗CD79b免疫結合物治療濾泡性淋巴瘤之方法
|
US11780911B2
(en)
|
2019-05-23 |
2023-10-10 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
EP3976067A1
(en)
|
2019-05-28 |
2022-04-06 |
Vib Vzw |
Cd8+ t-cells lacking plexins and their application in cancer treatment
|
WO2020239945A1
(en)
|
2019-05-28 |
2020-12-03 |
Vib Vzw |
Cancer treatment by targeting plexins in the immune compartment
|
CN113939531A
(zh)
|
2019-06-03 |
2022-01-14 |
詹森生物科技公司 |
用于治疗银屑病关节炎的抗tnf抗体组合物和方法
|
MX2021014882A
(es)
|
2019-06-03 |
2022-03-25 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
|
JPWO2020246567A1
(ja)
|
2019-06-05 |
2020-12-10 |
|
|
KR20220017430A
(ko)
|
2019-06-05 |
2022-02-11 |
추가이 세이야쿠 가부시키가이샤 |
항체 절단 부위 결합 분자
|
CN114008713A
(zh)
|
2019-06-07 |
2022-02-01 |
中外制药株式会社 |
信息处理***、信息处理方法、程序、以及制备抗原结合分子或蛋白质的方法
|
AU2020291527A1
(en)
|
2019-06-11 |
2022-01-20 |
Alector Llc |
Anti-Sortilin antibodies for use in therapy
|
CN114206938A
(zh)
|
2019-06-20 |
2022-03-18 |
国家医疗保健研究所 |
抗蛋白酶nexin-1构象单域抗体及其用途
|
WO2020260329A1
(en)
|
2019-06-26 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Fusion of an antibody binding cea and 4-1bbl
|
WO2020260326A1
(en)
|
2019-06-27 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
EP4004046A1
(en)
|
2019-07-22 |
2022-06-01 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
US11667699B2
(en)
|
2019-07-31 |
2023-06-06 |
Alector Llc |
Anti-MS4A4A antibodies and methods of use thereof
|
BR112022001460A2
(pt)
|
2019-07-31 |
2022-03-22 |
Hoffmann La Roche |
Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
|
WO2021018925A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
CN114401743A
(zh)
|
2019-08-02 |
2022-04-26 |
法国国家健康和医学研究院 |
中和颗粒酶b用于向经历过心肌梗塞的受试者提供心脏保护
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
MX2022002963A
(es)
|
2019-09-12 |
2022-04-06 |
Genentech Inc |
Composiciones y metodos para tratar nefritis lupica.
|
MX2022003212A
(es)
|
2019-09-18 |
2022-04-25 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
TW202126699A
(zh)
|
2019-09-20 |
2021-07-16 |
美商建南德克公司 |
用於抗類胰蛋白酶抗體之投藥
|
US11667709B2
(en)
|
2019-09-24 |
2023-06-06 |
Industrial Technology Research Institute |
Anti-TIGIT antibodies and methods of use
|
CA3151406A1
(en)
|
2019-09-27 |
2021-04-01 |
Raymond D. Meng |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CN114829401A
(zh)
|
2019-09-27 |
2022-07-29 |
南京金斯瑞生物科技有限公司 |
抗vhh域抗体及其用途
|
EP4034560A1
(en)
|
2019-09-27 |
2022-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
AU2020360849A1
(en)
|
2019-09-30 |
2022-04-14 |
New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery |
Protein binders to iRhom2 epitopes
|
WO2021063968A1
(en)
|
2019-09-30 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and composition for diagnosing chronic obstructive pulmonary disease
|
TW202128756A
(zh)
|
2019-10-02 |
2021-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
EP4037714A1
(en)
|
2019-10-03 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
EP4037710A1
(en)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
BR112022007216A2
(pt)
|
2019-10-18 |
2022-08-23 |
Genentech Inc |
Métodos para tratamento de linfoma difuso, kit e imunoconjugado
|
WO2021078359A1
(en)
|
2019-10-21 |
2021-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of cubilin for the treatment of chronic kidney diseases
|
KR20220093323A
(ko)
|
2019-11-05 |
2022-07-05 |
에프. 호프만-라 로슈 아게 |
HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
EP4055053A1
(en)
|
2019-11-07 |
2022-09-14 |
Eisai R&D Management Co., Ltd. |
Anti-mesothelin eribulin antibody-drug conjugates and methods of use
|
CN114867737A
(zh)
|
2019-11-12 |
2022-08-05 |
国家医疗保健研究所 |
用于潜伏型弓形虫病的新血清学标志物
|
CN115151566A
(zh)
|
2019-11-15 |
2022-10-04 |
普利安特治疗公司 |
用于活化整合素的组合物和方法
|
EP4069301A1
(en)
|
2019-12-04 |
2022-10-12 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
EP4072682A1
(en)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antibodies having specificity to her4 and uses thereof
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
IL293827A
(en)
|
2019-12-13 |
2022-08-01 |
Alector Llc |
Anti-mertko antibodies and methods of using them
|
CA3163950A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
JP2023509359A
(ja)
|
2019-12-17 |
2023-03-08 |
フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド |
鉄依存性細胞分解の誘導物質との併用抗癌療法
|
JP7296467B2
(ja)
|
2019-12-18 |
2023-06-22 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Hla-a2/mage-a4に結合する抗体
|
JP2023507083A
(ja)
|
2019-12-19 |
2023-02-21 |
クイデル コーポレーション |
モノクローナル抗体融合物
|
EP4081294A2
(en)
|
2019-12-23 |
2022-11-02 |
Genentech, Inc. |
Apolipoprotein l1-specific antibodies and methods of use
|
AU2020414996A1
(en)
|
2019-12-23 |
2022-07-14 |
Eisai R&D Management Co., Ltd. |
Method for producing eribulin-based antibody-drug conjugate
|
WO2021131021A1
(ja)
|
2019-12-27 |
2021-07-01 |
中外製薬株式会社 |
抗ctla-4抗体およびその使用
|
BR112022012969A2
(pt)
|
2020-01-09 |
2022-09-06 |
Hoffmann La Roche |
Moléculas de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, composição farmacêutica, usos da molécula de ligação, métodos para produzir a molécula de ligação, tratar um indivíduo com câncer e suprarregular ou prolongar a atividade de células t citotóxicas em um indivíduo com câncer
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
US20230076415A1
(en)
|
2020-01-17 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
KR20220136378A
(ko)
|
2020-01-31 |
2022-10-07 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 rna 백신을 이용하여 네오에피토프-특이적 t 세포를 유도하는 방법
|
CN115397848A
(zh)
|
2020-02-05 |
2022-11-25 |
拉利玛生物医药公司 |
Tat肽结合蛋白及其用途
|
AU2021218927A1
(en)
|
2020-02-10 |
2022-09-22 |
Shanghai Escugen Biotechnology Co., Ltd. |
Claudin 18.2 antibody and use thereof
|
CA3167299A1
(en)
|
2020-02-10 |
2021-08-19 |
Shanghai Escugen Biotechnology Co., Ltd. |
Cldn18.2 antibody and use thereof
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
CN113248611A
(zh)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
JP2023514957A
(ja)
|
2020-02-28 |
2023-04-12 |
オレガ・バイオテック |
Ctla4阻害剤及びil-17b阻害剤に基づく複合療法
|
AU2021236306A1
(en)
|
2020-03-13 |
2022-09-15 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
AU2021236660A1
(en)
|
2020-03-19 |
2022-08-18 |
Genentech, Inc. |
Isoform-selective anti-TGF-beta antibodies and methods of use
|
MX2022011752A
(es)
|
2020-03-24 |
2022-10-18 |
Genentech Inc |
Agentes de fijacion a tie2 y metodos de uso.
|
KR20220159426A
(ko)
|
2020-03-26 |
2022-12-02 |
제넨테크, 인크. |
감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
|
CA3178461A1
(en)
|
2020-03-31 |
2021-10-07 |
Biotalys NV |
Anti-fungal polypeptides
|
BR112022017526A2
(pt)
|
2020-03-31 |
2022-10-18 |
Chugai Pharmaceutical Co Ltd |
Método para produzir moléculas de ligação de antígeno multiespecíficas
|
JP2023519962A
(ja)
|
2020-03-31 |
2023-05-15 |
アレクトル エルエルシー |
抗mertk抗体及びその使用方法
|
US20230107644A1
(en)
|
2020-04-01 |
2023-04-06 |
University Of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2021198511A1
(en)
|
2020-04-03 |
2021-10-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of sars-cov-2 infection
|
WO2021209402A2
(en)
|
2020-04-15 |
2021-10-21 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
EP4144758A4
(en)
|
2020-04-22 |
2024-05-15 |
Mabwell Shanghai Bioscience Co Ltd |
SINGLE VARIABLE DOMAIN ANTIBODIES TARGETING AND DERIVED FROM HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1)
|
BR112022021441A2
(pt)
|
2020-04-24 |
2022-12-13 |
Genentech Inc |
Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
|
IL296664A
(en)
|
2020-04-24 |
2022-11-01 |
Hoffmann La Roche |
Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
|
TW202206100A
(zh)
|
2020-04-27 |
2022-02-16 |
美商西健公司 |
癌症之治療
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
SG11202112792WA
(en)
|
2020-04-28 |
2021-12-30 |
Univ Rockefeller |
Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
|
CA3177562A1
(en)
|
2020-05-03 |
2021-11-11 |
Tong Zhu |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
EP4149558A1
(en)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
US20230212260A1
(en)
|
2020-05-15 |
2023-07-06 |
Apogenix Ag |
Multi-specific immune modulators
|
WO2021229104A1
(en)
|
2020-05-15 |
2021-11-18 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
AU2021276332A1
(en)
|
2020-05-19 |
2022-11-17 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
AU2021274883A1
(en)
|
2020-05-20 |
2022-12-01 |
Centre National De La Recherche Scientifique - Cnrs - |
Synthetic single domain library
|
CA3182333A1
(en)
|
2020-05-20 |
2021-11-25 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
EP4153222A1
(en)
|
2020-05-20 |
2023-03-29 |
Takeda Vaccines, Inc. |
Method for detection of zika virus specific antibodies
|
WO2021236225A1
(en)
|
2020-05-20 |
2021-11-25 |
Takeda Vaccines, Inc. |
Method for detection of zika virus specific antibodies
|
WO2021236223A1
(en)
|
2020-05-20 |
2021-11-25 |
Takeda Vaccines, Inc. |
Method for determining the potency of antigens
|
IL298668A
(en)
|
2020-05-29 |
2023-01-01 |
23Andme Inc |
Antibodies against cd200r1 and methods of using them
|
WO2021245224A1
(en)
|
2020-06-05 |
2021-12-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating ocular diseases
|
CA3184645A1
(en)
|
2020-06-05 |
2021-12-09 |
Eisai R&D Management Co., Ltd. |
Anti-bcma antibody-drug conjugates and methods of use
|
MX2022015206A
(es)
|
2020-06-08 |
2023-01-05 |
Hoffmann La Roche |
Anticuerpos anti-hbv y metodos de uso.
|
KR20230023727A
(ko)
|
2020-06-11 |
2023-02-17 |
제넨테크, 인크. |
나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
WO2021257124A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
CN115916826A
(zh)
|
2020-06-19 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
与CD3和FolR1结合的抗体
|
KR20230025667A
(ko)
|
2020-06-19 |
2023-02-22 |
에프. 호프만-라 로슈 아게 |
프로테아제 활성화된 t 세포 이중특이성 항체
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
CN115698084A
(zh)
|
2020-06-19 |
2023-02-03 |
豪夫迈·罗氏有限公司 |
与cd3结合的抗体
|
CN115916825A
(zh)
|
2020-06-19 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
与cd3和cd19结合的抗体
|
CA3183475A1
(en)
|
2020-06-22 |
2021-12-30 |
Thomas Huber |
Anti-il-36 antibodies and methods of use thereof
|
JP2023530760A
(ja)
|
2020-06-23 |
2023-07-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Her2を標的とするアゴニストCD28抗原結合分子
|
EP4172192A1
(en)
|
2020-06-24 |
2023-05-03 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
JP2023531067A
(ja)
|
2020-06-25 |
2023-07-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd3/抗cd28二重特異性抗原結合分子
|
CN116096906A
(zh)
|
2020-06-29 |
2023-05-09 |
旗舰创业创新五公司 |
工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
|
US20230265211A1
(en)
|
2020-06-29 |
2023-08-24 |
Inserm (Institut National De La Santé Et De Ls Recherche Médicale) |
Anti-protein s single-domain antibodies and polypeptides comprising thereof
|
WO2022008597A1
(en)
|
2020-07-08 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of infectious diseases
|
CN115812149A
(zh)
|
2020-07-13 |
2023-03-17 |
基因泰克公司 |
用于预测多肽免疫原性的基于细胞的方法
|
JP2023534458A
(ja)
|
2020-07-17 |
2023-08-09 |
ジェネンテック, インコーポレイテッド |
抗Notch2抗体及び使用方法
|
TW202216215A
(zh)
|
2020-07-21 |
2022-05-01 |
美商建南德克公司 |
Brm降解之抗體結合化學誘導物及其方法
|
US20230266332A1
(en)
|
2020-07-28 |
2023-08-24 |
Inserm (Institut National De La Santè Et De La Recherch Médicale) |
Methods and compositions for preventing and treating a cancer
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
EP4189071A1
(en)
|
2020-08-03 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
JP2023537683A
(ja)
|
2020-08-07 |
2023-09-05 |
ジェネンテック, インコーポレイテッド |
ポリペプチド免疫原性を予測するためのt細胞ベースの方法
|
CA3187245A1
(en)
|
2020-08-17 |
2022-02-24 |
Sebastien Mercx |
Recombinant immunotoxin comprising a ribotoxin or rnase
|
CN114106173A
(zh)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
抗ox40抗体、其药物组合物及应用
|
KR20230056766A
(ko)
|
2020-08-28 |
2023-04-27 |
제넨테크, 인크. |
숙주 세포 단백질의 CRISPR/Cas9 다중 녹아웃
|
JP2023539279A
(ja)
|
2020-08-31 |
2023-09-13 |
ジェネンテック, インコーポレイテッド |
抗体を産生するための方法
|
KR20230086690A
(ko)
|
2020-09-14 |
2023-06-15 |
아이크노스 사이언스 에스. 아. |
Il1rap에 결합하는 항체 및 이의 용도
|
EP4216943A1
(en)
|
2020-09-24 |
2023-08-02 |
Vib Vzw |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
IL300543A
(en)
|
2020-09-24 |
2023-04-01 |
Hoffmann La Roche |
Prevention or reduction of adverse effects associated with a bispecific T-cell antibody
|
WO2022064049A1
(en)
|
2020-09-28 |
2022-03-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for diagnosing brucella infection
|
AU2021349385A1
(en)
|
2020-09-28 |
2023-05-25 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
WO2022072523A1
(en)
|
2020-09-30 |
2022-04-07 |
Seagen Inc. |
Uveal melanoma treatment using sea-cd40
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
WO2022076865A1
(en)
|
2020-10-09 |
2022-04-14 |
Takeda Vaccines, Inc. |
Methods for determining complement-fixing antibodies
|
WO2022079270A1
(en)
|
2020-10-16 |
2022-04-21 |
Université D'aix-Marseille |
Anti-gpc4 single domain antibodies
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
CN116685325A
(zh)
|
2020-10-20 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
|
WO2022084300A1
(en)
|
2020-10-20 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring form of coronavirus infection
|
EP4232476A2
(en)
|
2020-10-21 |
2023-08-30 |
Boehringer Ingelheim International GmbH |
Agonistic trkb binding molecules for the treatment of eye diseases
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
CN116635419A
(zh)
|
2020-10-30 |
2023-08-22 |
豪夫迈·罗氏有限公司 |
使用CEA CD3双特异性抗体和TGFβ信号传导抑制剂的癌症治疗
|
AR123997A1
(es)
|
2020-11-04 |
2023-02-01 |
Univ Rockefeller |
ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2
|
IL302217A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates
|
IL302396A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
|
JP2023549140A
(ja)
|
2020-11-04 |
2023-11-22 |
マイエロイド・セラピューティクス,インコーポレーテッド |
操作されたキメラ融合タンパク質組成物およびその使用方法
|
CA3196076A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
US20240002519A1
(en)
|
2020-11-05 |
2024-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
|
MX2023005306A
(es)
|
2020-11-10 |
2023-05-25 |
Hoffmann La Roche |
Prevencion o mitigacion de efectos adversos relacionados con agentes acopladores de linfocitos t.
|
PE20231556A1
(es)
|
2020-11-16 |
2023-10-03 |
Hoffmann La Roche |
Glucoformas de fab ricas en manosa
|
WO2022101481A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
CN117916261A
(zh)
|
2020-11-16 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
与靶向fap的cd40激动剂的组合疗法
|
MX2023005878A
(es)
|
2020-11-23 |
2023-06-05 |
Genentech Inc |
Metodos para modular las interacciones de la superficie de la celula huesped con sars-cov-2.
|
MX2023006172A
(es)
|
2020-11-27 |
2023-06-08 |
Genentech Inc |
Metodos para modular interacciones de superficie de celula huesped con citomegalovirus humano.
|
TW202229866A
(zh)
|
2020-12-01 |
2022-08-01 |
美商建南德克公司 |
顯示細胞表面蛋白質的生物囊泡及其相關方法
|
JP2023553399A
(ja)
|
2020-12-02 |
2023-12-21 |
アレクトル エルエルシー |
抗ソルチリン抗体の使用法
|
IL303656A
(en)
|
2020-12-17 |
2023-08-01 |
Hoffmann La Roche |
ANTI-HLA-G antibodies and their use
|
US20240058279A1
(en)
|
2020-12-21 |
2024-02-22 |
Flagship Pioneering Innovations V, Inc. |
Use of cell turnover factors for increasing tissue regeneration
|
AU2022206061A1
(en)
|
2021-01-06 |
2023-07-06 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
WO2022153194A1
(en)
|
2021-01-13 |
2022-07-21 |
Memorial Sloan Kettering Cancer Center |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
WO2022153212A1
(en)
|
2021-01-13 |
2022-07-21 |
Axon Neuroscience Se |
Antibodies neutralizing sars-cov-2
|
JP2024503658A
(ja)
|
2021-01-13 |
2024-01-26 |
メモリアル スローン-ケタリング キャンサー センター |
抗dll3抗体-薬物コンジュゲート
|
EP4277934A1
(en)
|
2021-01-14 |
2023-11-22 |
Institut Curie |
Her2 single domain antibodies variants and cars thereof
|
US20220227844A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
JP2024504390A
(ja)
|
2021-01-22 |
2024-01-31 |
バイワンキュア セラピューティクス, インコーポレイテッド |
抗her-2/trop-2構築物及びその使用
|
KR20230137295A
(ko)
|
2021-01-28 |
2023-10-04 |
난징 챔피언 바이오테크놀로지 컴퍼니 리미티드 |
접합체 및 이의 용도
|
WO2022175392A1
(en)
|
2021-02-17 |
2022-08-25 |
Vib Vzw |
Inhibition of slc4a4 in the treatment of cancer
|
JP2024507220A
(ja)
|
2021-02-19 |
2024-02-16 |
セリピオン, インコーポレイテッド |
パラオキソナーゼ融合ポリペプチドならびに関連する組成物および方法
|
IL305301A
(en)
|
2021-02-19 |
2023-10-01 |
Us Health |
Single domain antibodies neutralizing SARS CoV-2
|
EP4295157A1
(en)
|
2021-02-22 |
2023-12-27 |
Genentech, Inc. |
Methods for modulating host cell surface interactions with herpesviruses
|
KR20230150287A
(ko)
|
2021-02-26 |
2023-10-30 |
바이엘 악티엔게젤샤프트 |
비정상적 자궁 출혈의 치료에 사용하기 위한 il-11 또는 il-11ra의 억제제
|
TW202317612A
(zh)
|
2021-03-01 |
2023-05-01 |
美商艾希利歐發展股份有限公司 |
用於治療癌症的ctla4及pd1/pdl1抗體之組合
|
US20220340662A1
(en)
|
2021-03-01 |
2022-10-27 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
BR112023017035A2
(pt)
|
2021-03-01 |
2024-02-06 |
New York Soc For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surger |
Anticorpos humanizados contra irhom2, ácido nucleico, uso do anticorpo, composição farmacêutica, composição, método de tratamento e kit terapêutico
|
EP4301418A1
(en)
|
2021-03-03 |
2024-01-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
WO2022192647A1
(en)
|
2021-03-12 |
2022-09-15 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
IL305836A
(en)
|
2021-03-12 |
2023-11-01 |
Janssen Biotech Inc |
A method for treating psoriatic arthritis patients with insufficient response to TNF therapy with a specific anti-IL23 antibody
|
BR112023018353A2
(pt)
|
2021-03-12 |
2024-02-06 |
Janssen Biotech Inc |
Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
|
WO2022198192A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP4308118A1
(en)
|
2021-03-17 |
2024-01-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating melanoma
|
CA3213295A1
(en)
|
2021-03-17 |
2022-09-22 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
JP2024511078A
(ja)
|
2021-03-17 |
2024-03-12 |
レセプトス エルエルシー |
抗il-13抗体を用いてアトピー性皮膚炎を処置する方法
|
JP2024512002A
(ja)
|
2021-03-18 |
2024-03-18 |
アレクトル エルエルシー |
抗tmem106b抗体、及び、その使用方法
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
EP4314063A1
(en)
|
2021-03-23 |
2024-02-07 |
Alector LLC |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
KR20240012352A
(ko)
|
2021-03-23 |
2024-01-29 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
T 세포 림프종의 진단 및 치료 방법
|
CA3213771A1
(en)
|
2021-03-29 |
2022-10-06 |
Scirhom Gmbh |
Methods of treatment using protein binders to irhom2 epitopes
|
CN117157312A
(zh)
|
2021-03-30 |
2023-12-01 |
豪夫迈·罗氏有限公司 |
蛋白酶活化的多肽
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
AU2022255506A1
(en)
|
2021-04-08 |
2023-11-09 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
CR20230523A
(es)
|
2021-04-14 |
2024-01-23 |
Villaris Therapeutics Inc |
Anticuerpos anti-cd122 y usos de estos
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
EP4326871A1
(en)
|
2021-04-19 |
2024-02-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
|
CA3215965A1
(en)
|
2021-04-19 |
2022-10-27 |
Amy Shen |
Modified mammalian cells
|
WO2022223791A1
(en)
|
2021-04-23 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
EP4326271A1
(en)
|
2021-04-23 |
2024-02-28 |
F. Hoffmann-La Roche AG |
Prevention or mitigation of nk cell engaging agent-related adverse effects
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
KR20240005691A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
CN117396232A
(zh)
|
2021-05-12 |
2024-01-12 |
基因泰克公司 |
使用抗cd79b免疫缀合物治疗弥漫性大b细胞淋巴瘤的方法
|
BR112023023777A2
(pt)
|
2021-05-14 |
2024-01-30 |
Genentech Inc |
Anticorpos isolados, composição farmacêutica, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, método para produzir um anticorpo, método para tratar uma condição associada à perda de função de trem2, método para reduzir os níveis de strem2 e uso de um anticorpo
|
WO2022242892A1
(en)
|
2021-05-17 |
2022-11-24 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
KR20240010469A
(ko)
|
2021-05-21 |
2024-01-23 |
제넨테크, 인크. |
관심 재조합 생성물의 생성을 위한 변형된 세포
|
TW202314247A
(zh)
|
2021-05-25 |
2023-04-01 |
美商思進公司 |
量化抗cd40抗體之方法
|
TW202306979A
(zh)
|
2021-05-26 |
2023-02-16 |
美商建南德克公司 |
調節人類巨細胞病毒與宿主細胞表面交互作用之方法
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
WO2022254379A1
(en)
|
2021-06-04 |
2022-12-08 |
Boehringer Ingelheim International Gmbh |
Anti-sirp-alpha antibodies
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
CA3216220A1
(en)
|
2021-06-09 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
EP4355786A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
EP4355778A1
(en)
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Novel tri-specific binding molecules
|
US20230174651A1
(en)
|
2021-06-23 |
2023-06-08 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
CR20240026A
(es)
|
2021-06-25 |
2024-03-14 |
Chugai Seiyaku Kk |
Anticuerpo anti-ctla-4
|
KR20240024255A
(ko)
|
2021-06-25 |
2024-02-23 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체의 사용
|
KR20240026507A
(ko)
|
2021-06-29 |
2024-02-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
|
CA3223534A1
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
CN117957251A
(zh)
|
2021-07-09 |
2024-04-30 |
詹森生物科技公司 |
用于制备抗tnf抗体组合物的制造方法
|
WO2023281120A1
(en)
|
2021-07-09 |
2023-01-12 |
Luxembourg Institute Of Health (Lih) |
Dimeric protein complexes and uses thereof
|
AU2022306973A1
(en)
|
2021-07-09 |
2024-02-22 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
WO2023281462A1
(en)
|
2021-07-09 |
2023-01-12 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
WO2023285362A1
(en)
|
2021-07-12 |
2023-01-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-36 inhibitors for the treatment of netherton syndrome
|
US20230049152A1
(en)
|
2021-07-14 |
2023-02-16 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
KR20240036570A
(ko)
|
2021-07-22 |
2024-03-20 |
에프. 호프만-라 로슈 아게 |
이종이량체 Fc 도메인 항체
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
KR20240038008A
(ko)
|
2021-07-28 |
2024-03-22 |
에프. 호프만-라 로슈 아게 |
암 치료 방법 및 조성물
|
WO2023010080A1
(en)
|
2021-07-30 |
2023-02-02 |
Seagen Inc. |
Treatment for cancer
|
WO2023006975A2
(en)
|
2021-07-30 |
2023-02-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric proteins and methods of immunotherapy
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
WO2023028591A1
(en)
|
2021-08-27 |
2023-03-02 |
Genentech, Inc. |
Methods of treating tau pathologies
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
TW202313695A
(zh)
|
2021-09-15 |
2023-04-01 |
法商感應檢查療法公司 |
抗btn3a抗體在製備用於治療腫瘤的藥物的用途
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
TW202330038A
(zh)
|
2021-09-30 |
2023-08-01 |
美商思進公司 |
用於治療癌症之b7-h4抗體-藥物結合物
|
WO2023060086A1
(en)
|
2021-10-04 |
2023-04-13 |
Takeda Vaccines, Inc. |
Methods for determining norovirus-reactive antibodies
|
US20230190807A1
(en)
|
2021-10-06 |
2023-06-22 |
Immatics Biotechnologies Gmbh |
Tcr compounds, compositions, and methods of treating
|
WO2023057601A1
(en)
|
2021-10-06 |
2023-04-13 |
Biotalys NV |
Anti-fungal polypeptides
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
CA3234598A1
(en)
|
2021-10-27 |
2023-05-04 |
Daniel Olive |
Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
TW202325742A
(zh)
|
2021-11-01 |
2023-07-01 |
瑞士商赫孚孟拉羅股份公司 |
使用 HLA-A2/WT1 x CD3 雙特異性抗體及 4-1BB (CD137) 促效劑治療癌症
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
US20230192886A1
(en)
|
2021-11-08 |
2023-06-22 |
Immatics Biotechnologies Gmbh |
Adoptive cell therapy combination treatment and compositions thereof
|
US20230272082A1
(en)
|
2021-11-09 |
2023-08-31 |
Sensei Biotherapeutics, Inc. |
Anti-vista antibodies and uses thereof
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
US20230151087A1
(en)
|
2021-11-15 |
2023-05-18 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
WO2023088889A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
CD137 ligands
|
WO2023088876A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
Multi-specific immune modulators
|
TW202337494A
(zh)
|
2021-11-16 |
2023-10-01 |
美商建南德克公司 |
用莫蘇妥珠單抗治療全身性紅斑狼瘡(sle)之方法及組成物
|
WO2023095000A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
WO2023094525A1
(en)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
WO2023094698A1
(en)
|
2021-11-29 |
2023-06-01 |
Ose Immunotherapeutics |
Specific antagonist anti-sirpg antibodies
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
TW202339797A
(zh)
|
2021-12-14 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
使用hla-a2mage-a4xcd3雙特異性抗體及4-1bb(cd137)促效劑治療癌症
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023117834A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Agonistic ltbr antibodies and bispecific antibodies comprising them
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
EP4209508A1
(en)
|
2022-01-11 |
2023-07-12 |
Centre national de la recherche scientifique |
Nanobodies for the deneddylating enzyme nedp1
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
WO2023144235A1
(en)
|
2022-01-27 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
EP4231017A1
(en)
|
2022-02-17 |
2023-08-23 |
Promise Proteomics |
Detection and quantification of anti-drug antibodies and anti-self antibodies
|
WO2023156634A1
(en)
|
2022-02-17 |
2023-08-24 |
Atb Therapeutics |
Recombinant immunotoxin comprising a ribosome inactivating protein
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2023170247A1
(en)
|
2022-03-11 |
2023-09-14 |
Mablink Bioscience |
Antibody-drug conjugates and their uses
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
EP4257609A1
(en)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Combination therapies based on pd-1 inhibitors and sik3 inhibitors
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
TW202400243A
(zh)
|
2022-04-12 |
2024-01-01 |
日商衛材R&D企管股份有限公司 |
基於艾日布林的抗體–藥物軛合物及其使用方法
|
US20230406930A1
(en)
|
2022-04-13 |
2023-12-21 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
JP2024517042A
(ja)
|
2022-04-13 |
2024-04-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd20/抗cd3二重特異性抗体の薬学的組成物及び使用方法
|
WO2023198851A1
(en)
|
2022-04-14 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023212298A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Bispecific antibodies and methods of treating ocular disease
|
WO2023212294A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Angiopoietin-related protein 7-specific antibodies and uses thereof
|
WO2023212293A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Complement factor h related 4-specific antibodies and uses thereof
|
TW202406934A
(zh)
|
2022-05-03 |
2024-02-16 |
美商建南德克公司 |
抗Ly6E抗體、免疫結合物及其用途
|
WO2023217904A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023218431A1
(en)
|
2022-05-13 |
2023-11-16 |
BioNTech SE |
Rna compositions targeting hiv
|
US20230374122A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
|
US20230416412A1
(en)
|
2022-05-31 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Prevention or mitigation of t-cell engaging agent-related adverse effects
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023237661A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
EP4299124A1
(en)
|
2022-06-30 |
2024-01-03 |
Universite De Montpellier |
Anti-mglur2 nanobodies for use as biomolecule transporter
|
WO2024008274A1
(en)
|
2022-07-04 |
2024-01-11 |
Universiteit Antwerpen |
T regulatory cell modification
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024013234A1
(en)
|
2022-07-13 |
2024-01-18 |
Institut National de la Santé et de la Recherche Médicale |
Methods for diagnosis, prognosis, stratification and treating of myocarditis
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20240052065A1
(en)
|
2022-07-15 |
2024-02-15 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024018003A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Extracellular vesicles functionalized with an erv syncitin and uses thereof for cargo delivery
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024020579A1
(en)
|
2022-07-22 |
2024-01-25 |
Bristol-Myers Squibb Company |
Antibodies binding to human pad4 and uses thereof
|
WO2024018426A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
WO2024023246A1
(en)
|
2022-07-28 |
2024-02-01 |
Philogen S.P.A. |
Antibody binding to pd1
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
TW202405020A
(zh)
|
2022-07-29 |
2024-02-01 |
美商阿列克特有限責任公司 |
轉鐵蛋白受體抗原結合域及其用途
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024033362A1
(en)
|
2022-08-08 |
2024-02-15 |
Atb Therapeutics |
Humanized antibodies against cd79b
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
WO2024040020A1
(en)
|
2022-08-15 |
2024-02-22 |
Absci Corporation |
Quantitative affinity activity specific cell enrichment
|
WO2024038112A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Improved anti-albumin nanobodies and their uses
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
WO2024068705A1
(en)
|
2022-09-29 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|
WO2024074498A1
(en)
|
2022-10-04 |
2024-04-11 |
Imcheck Therapeutics |
Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
WO2024079010A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and cd38 antibodies
|
WO2024079009A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and proteasome inhibitors
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|